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ABSTRACT OF DISSERTATION 
EXPOSURE, GENETICS, AND CHRONIC BERYLLIUM DISEASE 
Beryllium is a low-density metal with unique properties used in a number of 
industries including automotive, electronics, communications, medical, defense, and 
aerospace. Workers exposed to aerosols generated by the fabrication of beryllium-
containing materials are at risk for developing beryllium sensitization (BeS) and chronic 
beryllium disease (CBD). While several studies have documented that higher exposures 
are associated with higher rates of BeS and CBD, there have been consistent difficulties 
in defining the nature of the exposure-response relationship. In addition, several studies 
have identified at least one genetic host factor, a glutamic acid at position 69 (E69) of the 
HLA-DPB1 gene, that increases individual susceptibility to BeS and CBD. The 
relationship between beryllium exposure and carriage of the E69 genotype has not been 
well studied. This dissertation research was designed to evaluate the relationship between 
beryllium exposure and E69 in the risk of BeS and CBD. 
In Chapter 2, the combined risk of BeS and CBD was evaluated as a function of 
beryllium exposure and carriage of any E69 genotype in a case-control study of current 
and former workers from a U.S. nuclear weapons production facility, the Y-12 National 
Security Complex (Oak Ridge, TN). Study participants included 35 individuals with BeS, 
19 with CBD, and 127 controls with potential beryllium exposure. For this study, 
beryllium exposures were assessed through a combination of worker interviews and 
“expert” industrial hygiene assessment. After removing the confounding effect of 
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potential beryllium exposure at another facility, multivariate models showed a seven-fold 
(OR 7.41, 95% CI: 2.31-23.75) increased odds for BeS and CBD among HLA-DPB1 E69 
carriers and a five-fold (OR 5.13, 95% CI: 1.59 to 16.57) increased odds for those 
exposed over the median cumulative beryllium exposure (1.8 µg/m3-years). Those with 
both risk factors had additive odds for BeS/CBD (OR 38.0, 95% CI: 6.02 – 240). The 
study demonstrated that HLA-DPB1 E69 carriage and high exposure to beryllium 
appeared to be additive risk factors for the development of BeS and CBD. In addition, 
from this study, it appeared that the magnitude of risk associated with either elevated 
beryllium exposure or carriage of E69 was similar. 
In Chapter 3, the risk of BeS and CBD was evaluated separately as a function of 
beryllium exposure and specific E69 genotype in a case-control study of former workers 
from a decommissioned U.S. nuclear weapons production facility, Rocky Flats 
Environmental Technology Site (RFETS, Arvada, CO). Study participants included 70 
individuals with BeS, 61 with CBD, and 255 controls with potential beryllium exposure. 
For this study, beryllium exposures were assessed through a combination of worker 
interviews and assessment of task exposures based on facility-specific and industry-wide 
industrial hygiene exposure measurements. This study showed that different HLA-DPB1 
E69 alleles or more than one copy of an E69 allele may confer differential risk of BeS 
and CBD. Carriage of a single, more common HLA-DPB1 *02 allele conferred a 12-fold 
increased odds for BeS (OR: 12.01, 95% CI: 4.28-33.71) and a three-fold increased odds 
for CBD (OR: 3.46, 95% CI: 1.42-8.43). A single copy of a rarer non-*02 E69 allele 
conferred a 30-fold increased odds for BeS (OR: 29.54, 95% CI: 10.33-84.53) and a 
nearly 12-fold increased odds for CBD (OR: 11.97 95% CI: 5.12-28.00), and two E69 
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allele copies conferred a 55-fold increased odds for BeS (OR: 55.68, 95% CI: 14.80-
209.40) and a 22-fold increased odds for CBD (OR: 22.54, 95% CI: 7.00-72.62). 
Lifetime weighted beryllium exposure conferred an approximate two-fold increased odds 
of CBD (OR: 2.22, 95% CI: 1.21-4.07) regardless of E69 genotype again suggesting an 
additive relationship between E69 and exposure. Beryllium exposure was not a 
significant predictor of BeS. 
The study in Chapter 4 compared three different, but related, retrospective 
exposure assessment methods applied to the participants of the case-control study in 
Chapter 3. Beryllium exposures for each participant were assessed using three different 
methods: 1) a traditional job exposure matrix (JEM method) that assigned beryllium 
exposures at the job title level based on interviews with a few workers in each job title 
and assessment of available industrial hygiene exposure measurements for this job title; 
2) individual worker interviews evaluating the tasks each worker performed followed by 
“expert” assessment of task exposures by two industrial hygienists based solely on 
professional judgment (IH rating method) as was used in Chapter 2 of this dissertation, 
and; 3) individual worker interviews as described in #2 followed by extensive analyses of 
historical facility-specific and industry-wide data to assign exposures to tasks (IH data 
method), as was used in Chapter 3 of this dissertation. Results from this study suggested 
that a method of task exposure assessment relying solely on the professional judgment of 
industrial hygienists (IH rating method) performed similarly to a method involving 
extensive analyses of historical industrial hygiene measurements (IH data method) in 
terms of rank order assessment of average task exposure. Participant exposure 
assignments using all three of the methods were significant predictors of increased CBD 
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risk with odds ratios ranging from 1.51 (95% CI: 1.03-2.22) for the JEM method to 2.50 
(95% CI: 1.47-4.26) for the IH data method, both in terms of each unit increase in 
lifetime-weighted average exposure. Exposure misclassification likely attenuated the 
odds ratio point estimates for the odds of CBD by approximately 5% using the IH rating 
method and approximately 40% using the JEM method. 
 Taken together, the three studies confirm the importance of both beryllium 
exposure and E69 genotype in the risk of CBD suggesting an additive relationship 
between the two. Furthermore, it appears that BeS and CBD risk is differentially 
distributed among E69 genotypes with carriers of rarer non-*02 E69 alleles at higher risk. 
These studies also provide additional evidence on the importance of extremely low 
beryllium exposures in the risk of BeS even after adjusting for genetic susceptibility. 
Finally, the studies provide evidence to validate a more efficient exposure assessment 
method based on task exposures assessed using “expert” industrial hygiene assessment 
rather than resource-intensive compilation and analysis of thousands of exposure 
measurements. 
 
Michael V. Van Dyke 
Department of Environmental and Radiological Health Sciences 
Colorado State University 
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INTRODUCTION, GOALS, AND BACKGROUND 
 
Introduction 
Workers exposed to aerosols generated by the production or fabrication of 
beryllium-containing materials are at risk for beryllium sensitization (BeS) and chronic 
beryllium disease (CBD). The risk of BeS/CBD varies by workplace and by exposure 
level. However, prevalences of up to 15% for BeS and 8% for CBD have been 
documented in previous studies.(1, 2) With conservative estimates of the exposed U.S. 
workforce up to 134,000, and increasing use of beryllium in non-traditional industries, 
chronic beryllium disease represents a significant, occupational lung disease.(3)  
Exposure to beryllium causes an immune reaction or BeS in susceptible 
individuals. This immune reaction is observed as T-Cell proliferation in beryllium 
stimulated peripheral blood and is measured using the beryllium lymphocyte proliferation 
test (BeLPT).(2, 4, 5) In some individuals, the immune system is unable to regulate the 
response to beryllium resulting in T-Cell activation and recruitment of macrophages to 
encapsulate beryllium particles in the lung.(6) This results in granuloma formation and 
pulmonary impairment due to the reduction in alveolar surface area available for gas 
exchange. 
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Exposure and genetic factors appear to play a role both in the ability of an 
individual to become sensitized and in the progression from BeS to CBD. While it is 
clear that higher exposures lead to higher rates of BeS/CBD, the exposure-response 
relationship does not appear to be linear.(7-9) Some explanations proposed for this lack of 
a linear exposure-response relationship have included exposure to different physical or 
chemical forms of beryllium(10) (i.e., beryllium metal versus beryllium oxide), exposure 
to smaller particle sizes more likely to reach the alveolar region of the lung(11-14), and the 
failure to account for dermal exposure to beryllium(15-17). Most epidemiological studies of 
beryllium disease have been cross sectional in design, and many have suffered from 
exposure misclassification and lack of power to detect small differences. However, the 
epidemiological evidence clearly shows the presence of a sub-population of individuals 
who develop BeS at extremely low exposures.(7, 8, 18) This observation has led to research 
to define the genetic characteristics of this sensitive sub-population. 
Genetic studies have shown significant increased risk of BeS/CBD associated 
with a particular group of alleles coding for glutamic acid at position 69 (E69) of the 
human leukocyte antigen class II DP beta one (HLA DPB1) region on chromosome 
six.(19-28) This region is part of the human major histocompatibility complex (MHC). As 
the HLA Class II group of genes have been shown to encode cell-surface proteins for 
presentation of cell processed antigens to T-Cells(29), it is likely this is a functional 
genetic variant important in the mechanism of BeS/CBD. Some functionality has been 
confirmed in that proliferation of T-Cells in response to beryllium stimulation can be 
blocked in vitro by the addition of antibodies to HLA-DP.(30)  Molecular biology research 
has identified that HLA-DPB1 encodes the beta chain of the antigen binding groove and 
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substitutions at position 69 affect the electrostatic potential and likely the ability to bind 
the beryllium antigen.(31, 32) However, since the U.S. population carrier frequency of HLA 
DPB1 E69 is somewhere between 30% and 40%(33) and the prevalence of BeS/CBD in 
exposed populations is only 1% to 15%(1, 18), it is clear that there are additional factors, 
likely genetic and exposure related that play a role in the pathogenesis of BeS/CBD. In 
the only study to evaluate the combination of exposure and genetics, the effects were 
found to be at least additive.(21)  This study involved only six cases of CBD and 121 
controls identifying relatively high – albeit, imprecise - odds ratios of 10.1 (95% CI: 1.1-
93.7) for high exposure and 11.8 (95% CI: 1.3-108.8) for E69.(21) 
 
Goals of dissertation research 
Previous studies have lacked the power or exposure assessment to investigate the 
individual contribution of genetic and exposure effects, as well as, the interaction of these 
effects, in the development of BeS/CBD. A better understanding of the differences in 
exposure-response for BeS/CBD among genetically susceptible individuals is critical for 
worker protection. The overall goal of this dissertation research was to identify the 
contribution of exposure and genetic effects in the development of BeS/CBD to better 
understand the pathogenesis of the disease and provide important information to policy 
makers considering a new beryllium exposure standard. 
 
Specific aims 
1. Examine genetic and exposure effects in relation to BeS/CBD via a case-control 
study with participants enrolled from a nuclear weapons production facility that 
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has not been previously studied (Y-12 National Security Complex, Oak Ridge, 
TN). Due to limited industrial hygiene data, exposure assessment for this cohort 
was completed using a method combining individual interviews and “expert 
assessment” by industrial hygienists. This study tested two main hypotheses: 1) 
genetic variant, specifically, HLA DPB1 E69, and beryllium exposure contribute 
individually to the development of BeS/CBD; and 2) the average exposure 
resulting in BeS/CBD is lower for HLA DPB1 E69 carriers compared to non-
carriers. This was the first gene-environment study on BeS/CBD to combine HLA 
genotyping with semi-quantitative exposure assignments. 
2. Examine additional genetic and exposure factors, including gene-exposure 
interaction, effect of multiple DPB1 E69 encoding alleles, and the effect of 
carriage of rarer non-*02 DPB1 E69 encoding alleles in BeS/CBD via case-
control analysis of a larger cohort (Rocky Flats Environmental Technology Site, 
Arvada, CO) that provides more statistical power and more complete industrial 
hygiene data for exposure assessment. For this study, exposure assessment was 
completed using two methods: 1) a method combining individual interviews and 
industrial hygiene exposure data; and 2) individual interviews and “expert 
assessment” by industrial hygienists as in the study in specific aim 1. This larger 
study tested three main hypotheses: 1) there is an additive gene-exposure 
interaction between exposure and HLA DPB1 E69 status; 2) additional copies of 
E69 encoding alleles confer increased risk of BeS/CBD; and 3) carriers of rarer 
non-*02 alleles are at increased risk of BeS/CBD compared to those with the 
more common *02 alleles. 
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3. Compare the two exposure assessment methods used in specific aim two. 
Comparison of the two methods will allow results from the study in specific aim 
one to be compared to results using a more conventional exposure assessment 
method based on industrial hygiene data. This aim will test the hypothesis that a 
method using a combination of individual interviews and expert assessment by 
industrial hygienists will provide relative exposure assignments comparable to 
those produced using individual interviews and industrial hygiene exposure data.  
 
Background and significance 
Beryllium use and number exposed 
Beryllium is a low-density metal with unique properties that make it desirable for 
use in a number of industries including automotive, electronics, communications, 
medical, defense, and aerospace. Beryllium is three times lighter than aluminum and has 
a specific stiffness six times that of steel. The metal conducts heat well and is 
dimensionally stable over a wide range of temperatures. In addition, it is transparent to X-
rays and reflects neutrons. Beryllium has three commercially important forms: metal, 
oxide or ceramic, and alloy.(34) The world consumption in 2005 was 226 metric tons with 
a projected consumption of 529 metric tons in 2010.(35) 
The number of workers potentially exposed to beryllium is unknown. In the early 
1970s, NIOSH estimated a total of 21,233 U.S. workers exposed to beryllium based on a 
survey of 4,645 facilities in 66 different two digit SIC codes.(36) In the 1980s, this 
estimate was updated to 800,000 potentially exposed.(37) A more recent study using 
OSHA sampling data, estimated as many as 134,000 potentially exposed workers in U.S. 
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government and private industry.(3) However, this estimate likely underestimates the 
number exposed by not including downstream industries using beryllium products or 
facilities-related personnel who may have incidental exposure. A study of construction 
trades workers in the U.S. Department of Energy complex estimated that up to 230,000 
construction trades workers alone are potentially exposed to beryllium.(38) In the 
European Union, it has been estimated that over 67,000 individuals are occupationally 
exposed to beryllium.(39) Numbers exposed in most other parts of the world have not been 
clearly defined. 
 
History of beryllium disease 
Beryllium has been known for many years to cause two distinct types of 
pulmonary disease: acute beryllium disease (ABD) and chronic beryllium disease (CBD). 
The early literature on beryllium cites the development of an acute chemical pneumonitis 
after fairly high exposures to beryllium.(40, 41)  Eisenbud and Lisson(42) observed that 
nearly all workers exposed to concentrations exceeding 1 mg/m3 developed ABD while 
none exposed to less than 0.1 mg/m3 developed ABD, suggesting a clear exposure-
response for ABD. Exposure controls implemented in 1949 by the U.S. Atomic Energy 
Commission, including a 25 µg/m3 30-minute exposure limit, are credited with virtually 
eliminating ABD with the 15 cases reported after 1950 attributed to accidental 
exposures.(42) 
CBD was first described among workers at a fluorescent lamp manufacturing 
facility in Salem, MA and was attributed to use of beryllium containing phosphors.(43) 
This report described 17 beryllium exposed workers with common symptoms including 
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severe dyspnea and weight loss. The report concluded that beryllium caused a delayed 
onset chemical pneumonitis. In the 1940s and 1950s, additional cases were observed in 
workers from the primary beryllium industry as well as spouses of workers and residents 
from communities near beryllium producing facilities.(44-47) It was also noted that about 
15% of those diagnosed with ABD eventually developed CBD.(48) The first suggestion 
that CBD might be an immune mediated disease was published in 1951 by Sterner and 
Eisenbud.(47) The suggestion was based on several pieces of corroborating evidence: (1) 
the presence of severe cases of CBD with seemingly low exposures; (2) the lack of 
correlation between tissue levels of beryllium and the severity of disease; (3) an observed 
exposure-response at low airborne beryllium levels, but not at high levels; (4) the 
frequent occurrence of symptoms many years after exposure; and (5) the inability to 
produce similar effects in laboratory animals. Conclusive evidence for the granulomatous 
nature of beryllium disease was lacking until a detailed pathological review of 124 cases 
from the beryllium registry revealed clear granulomatous inflammation.(49) Evidence of a 
delayed hypersensitivity response to beryllium was demonstrated by Curtis in 1951 
through positive patch tests using 2% beryllium sulfate on 13/13 beryllium workers with 
observed beryllium-related dermatitis.(50)  
Based on early observations of CBD in beryllium production and fluorescent light 
manufacturing, Eisenbud and Machle developed an occupational exposure limit for 
beryllium. This limit was not based on any specific epidemiological evidence but instead, 
was extrapolated from existing standards for heavy metals and adjusted for the low 
atomic mass of beryllium. The standard was set by taking the average exposure limit for 
heavy metals of 100 µg/m3, dividing it by 20 to account for the approximate 20-fold 
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difference in atomic mass between heavy metals and beryllium, and dividing the result by 
2.5 as an “uncertainty” factor. The resulting limit was an eight-hour average exposure of 
2 µg/m3.(51-53) This level was eventually adopted as the OSHA standard in 1971, and 
remains unchanged to the present day.(54) The apparent success of this standard in 
reducing the incidence of CBD was outlined by Eisenbud in 1983 who reported that there 
were only 18 cases of CBD known to have been first exposed since 1962 and none with a 
first exposure beyond 1972.(42) 
As the cases of CBD appeared to be on the decline, important developments were 
being made in the immunology of CBD. In 1970, Hanifin et al. demonstrated in vitro 
proliferation of peripheral blood lymphocytes when blood cells from patch test positive 
beryllium exposed workers were stimulated with beryllium oxide or beryllium sulfate.(55) 
Subsequent studies verified this cell mediated immune response in both blood and lung 
cells from bronchoalveolar lavage.(56-59) The use of this peripheral blood lymphocyte 
proliferation as a diagnostic tool started in the 1980s.(58, 60, 61) In the late 1980s, 
investigators at National Jewish Health modernized this proliferation test by using a 
radiolabeled DNA precursor, tritiated thymidine, as a marker of proliferation which 
enabled better reproducibility and easier detection of proliferation.(2, 5) This test became 
the modern screening test known as the beryllium lymphocyte proliferation test (BeLPT). 
The BeLPT along with developments in bronchoalveolar lavage for determination of 
lymphocyte proliferation in lung cells and the ability to less invasively collect 
transbronchial biopsy specimens for pathological identification of granulomas using a 
bronchoscope enabled more definitive diagnosis of asymptomatic beryllium workers. 
Modern diagnosis of beryllium-related health effects classifies an individual with a 
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repeatable abnormal BeLPT and no evidence of granulomas on biopsy as beryllium 
sensitized (BeS). It is currently believed that BeS is a pre-cursor to CBD, with the only 
longitudinal study suggesting that the risk for BeS patients developing CBD is 
approximately 6 to 8% per year.(62) CBD is diagnosed as evidence of beryllium exposure 
and classically, granulomas on biopsy. These new diagnostic tools have allowed the 
detection of BeS and CBD before symptoms developed and have proven that CBD has 
continued to occur in modern industry. 
 
Beryllium epidemiology in the BeLPT era 
The use of the BeLPT enabled the study of many different beryllium exposed 
workforces, with the clear conclusion that the original beryllium standard of 2 µg/m3 has 
not eliminated beryllium disease in modern industry. As beryllium epidemiology has 
progressed with different methods depending on the particular industry, it is best 
presented as a progression of mounting evidence within each of the industries. 
 
Primary beryllium industry 
In the early 1990s, Kreiss et al.(9) performed a cross-sectional study at the primary 
facility where beryllium metal, alloys, and oxide products are produced in the U.S. This 
study involved full participation of 627 of the 655 current workers at the facility, 
excluding the five known cases of CBD. The prevalence of BeS was 6.9% (43/627) while 
the prevalence of CBD was 4.6% (29/632). High-risk processes were identified including 
ceramic fabrication and beryllium metal production (pebble plant and vacuum melting). 
Interestingly, two cases of CBD had worked only in purchasing and accounting. There 
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were no differences in cumulative beryllium exposure between cases and non-cases. As a 
result of this lack of exposure-response relationship, extensive particle size selective 
sampling was performed at this facility to determine whether the relationship might be 
obscured by using total mass sampling. Kent et al.(12) found significant associations 
between the mass of particles less than 10 µm and less than 3.5 µm on area samples from 
work areas with elevated risk of CBD and BeS. Significant associations were also 
observed for the calculated number and surface area concentration of particles less than 
10 µm with work areas with high prevalence of CBD.  
Another cross-sectional study at a separate beryllium production facility was 
completed in 2001.(1) This plant operated from 1957 to 1978 and the best estimate of 
cumulative employment puts the exposed population at 1,351. A total of 577 former 
employees completed the BeLPT screening in the study which identified 84 (14.5%) 
individuals with BeS including 44 (7.6%) individuals with CBD (or probable CBD). 
There were few findings of exposure-response relationships in this cohort with no 
differences in cumulative, mean, or peak exposures between CBD cases and normal 
individuals. Those with BeS were, in fact, identified as having consistently lower 
cumulative and mean exposures.  
 
Beryllium Ceramics Industry 
Kreiss et al.(7) conducted a cross-sectional study at the Tucson beryllium ceramics 
production facility in 1992 to examine the BeS and CBD rates and exposure response 
relationships. The activities of workers at this plant included powder pressing, extruding, 
and machining of fired and unfired ceramic materials. This study involved the entire 
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current workforce (n=139). Of the 136 employees with BeLPTs, eight (5.9%) were 
eventually identified as BeS of which six (4.4%) were diagnosed with CBD. Seven of the 
cases, including five CBD cases and both BeS cases, were involved in production 
activities and had performed machining operations. The remaining CBD case had worked 
only in the administrative area of the plant. The study identified a BeS prevalence of 
14.3% for employees who had ever been a machinist compared to 1.2% among other 
employees. Elevated BeS risk was not identified in employees ever performing dry 
pressing or other forming operations which were considered the dustiest operations at the 
plant. 
Exposure assignments at this facility were produced using a combination of 
standardized employee interviews, company-provided job histories, and air sampling 
results. The primary air sampling data available were daily weighted average (DWA) 
measurements, which are calculated 8-hour average concentrations based on time studies 
and multiple short, high volume, task-based air samples. There were also a limited 
number of full-shift personal sampling measurements which showed a correlation of 
approximately 0.65 with the DWA concentrations. Comparisons between cases and non-
cases showed no difference in duration, cumulative or average beryllium exposure. 
However, examination of exposure differences between machining and other operations 
revealed that, for the period in which most BeS cases had their initial exposure, 
machining had significantly higher percentages of personal samples  >0.1 µg/m3, 1.0 
µg/m3, and 2 µg/m3 compared to other processes in the plant. Calculated DWAs were 
also significantly higher for machining processes than for other processes. The most 
important finding of this study was the suggestion that exposures resulting in a 14.3 odds 
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ratio for BeS among beryllium machinists were mostly below the 2.0 µg/m3 OSHA 
standard.(7) Follow-up on this cohort in 2002 revealed additional disease burden with a 
17.6% cumulative incidence for BeS and 12.5% for CBD.(63) 
Henneberger et al.(64) extended the work of Kreiss et al.(7) at the Tucson ceramics 
facility in 1998 with a cross-sectional study of all current workers not previously 
diagnosed with CBD. During the period between this study and the previous Kreiss et 
al.(7) study, the company had worked to reduce machining exposures by enclosing 
machines and installing additional ventilation. All current employees as of January of 
1998, not previously diagnosed with CBD, were eligible to participate. Of those eligible, 
151 of 167 employees participated. Of those participating, roughly half (n=74) were 
short-term workers hired after the initial 1992 study with all but one of the remaining 77 
having participated in the 1992 study. Overall, 9.9% (15/151) of the workers were 
diagnosed as BeS including 10.4% (8/77) of long-term workers and 9.5% (7/74) short-
term workers. Over half (8/15) of those diagnosed with BeS were found to have CBD 
including 7 long-term workers and 1 short-term worker. Lapping, machining, forming, 
and packaging were identified as processes with statistically higher prevalences of BeS. 
Interestingly, risk for BeS in machining operations appeared to be elevated only for long-
term workers suggesting that process improvements since the 1992 study may have 
successfully reduced the risk for short-term workers. Non-significant trends were noted 
for increases in BeS prevalence with higher peak exposures for long-term workers and 
mean, cumulative, and peak exposures for short-term workers. The study also identified 
BeS in workers employed fewer than two years at the facility with mean exposures less 
than 0.1 µg/m3, cumulative exposures less than 0.1 µg-year/m3, and peak exposures less 
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than 0.4 µg/m3. Most importantly, this study highlights that company efforts to reduce 
exposures were not successfully preventing BeS.  
Based on the results of the 1998 Henneberger et al. study(64) the management of 
the beryllium ceramics facility embarked on a full-scale preventative program.(65) This 
program included numerous ventilation changes and enclosures to reduce airborne 
beryllium exposures, and extensive new personal protective equipment requirements 
including the requirement of respirators, long sleeves and gloves in production areas. In 
addition, administrative changes were implemented to reduce the spread of beryllium 
contamination to non-production areas. Most of these changes were completed by 
January of 2000 when medical surveillance of new workers began using the BeLPT. Of 
the 126 employees hired after January of 2000, 97 were eligible for inclusion in the study 
having worked for more than three months at the facility and completed two rounds of 
BeLPT screening. Of the 97, four were identified as BeS by the 2004 cut-off date for 
study inclusion. Three of the four employees had their first abnormal BeLPT “at hire” or 
the baseline time point and were not considered in the study’s estimated 2004 prevalence 
of 1.0% (1/97). Including workers with positive baseline BeLPTs would increase the 
estimated prevalence to 4.1% (4/97). The comparison presented by the authors between 
the 1.0% prevalence among the workers hired after implementation of the preventative 
program and the revised prevalence estimate of 8.7% among the workers hired between 
1993 and 1998 indicates the prevalence in the earlier cohort is 8.4 (95% CI, 1.04-68.49) 
times greater than that in the 2000-2004 cohort. This reported reduction in BeS occurred 
with little change in typical airborne beryllium exposures in production areas (0.20 µg/m3 
vs. 0.18 µg/m3). However, it is important to note the additional requirement of respiratory 
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protection for the 2000-2004 workers, which would reduce their actual exposures by 
approximately a factor of 10. The results of the study suggest a full-scale beryllium 
control program, including respiratory and skin protection likely reduces the incidence of 
BeS. However, equally important is that the risk for BeS does not appear to be eliminated 
by the implementation of such a comprehensive program. 
Kreiss et al.(66) performed a cross-sectional screening of a more diverse facility 
with specific departments where beryllium ceramics work was performed. BeLPT 
screening and chest radiographs on 505 current and former employees of this facility 
identified nine new cases of CBD. Screening was performed from 1989 to 1990 and the 
vast majority of beryllium operations were eliminated by 1976. Thus, due to latency, it is 
not surprising that all seven individuals identified as BeS were diagnosed with CBD. 
Prevalences of CBD ranged from 1.8% for all participants to 16% for employees who had 
worked in dusty dry pressing processes. Multivariate analysis identified odds ratios of 
11.4 (95% CI: 2.3-55.5) among those ever working in dry pressing, 8.9 (95% CI: 1.8-
42.8) among those ever working in process development, and increasing risk per year 
working with beryllium (OR: 2.2 at 10 year average). Interestingly, one case of CBD was 
identified in a worker whose hire date was more than seven years after beryllium 
operations had been terminated, but had performed dry sweeping in legacy beryllium 
areas. 
 
Beryllium fabrication: nuclear weapons 
One of the largest facilities fabricating beryllium parts was the Rocky Flats 
nuclear weapons plant located in Arvada, CO and later re-named Rocky Flats 
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Environmental Technology Site (RFETS). In the first coordinated study at the Rocky 
Flats plant, Kreiss et al.(2) conducted a cross-sectional study to evaluate the use of the 
BeLPT in the exposed workforce. The plant medical staff identified 58 workers with 
current beryllium exposure of which 51 participated in the study. At the time of the study, 
these 58 workers were considered the only workers at the plant to have significant 
exposure to beryllium with job titles including production machinist (41.2%), 
experimental operator (27.5%), experimental machinist (41.2%), engineer (5.9%), tool 
crib attendant (3.9%), and supervisor (3.9%). Although not specifically mentioned in the 
paper, a personal communication with one of the authors indicated that all of these 
workers were assigned to either building 444 or building 865 which were later identified 
as the two main beryllium production buildings. Among these 51 workers, six (11.8%) 
were identified as having an abnormal BeLPT, and of these six, four of the five who were 
clinically evaluated were diagnosed with CBD (7.8%). Compared to the normal workers, 
those with BeS were significantly older and a longer time period had elapsed since their 
first exposure to beryllium. This report was important in that it identified a rate of 
beryllium disease among exposed workers that was nearly twice the rate identified in 
previous reports. In addition, this study was one of the first to clearly document the 
importance of screening workers using BeLPT to identify early beryllium disease. 
Kreiss et al.(8) performed a second cross-sectional study in the late 1980s at Rocky 
Flats to determine CBD/BeS prevalence and risk factors among all employees. For this 
study, the entire currently employed workforce (those previously identified as BeS/CBD 
were excluded) was given a brief survey regarding beryllium exposure. Of the 3,305 
employees who returned the questionnaire, a stratified random sample of 1,247 were 
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selected to participate in a medical screening program. The stratification was based on 
answers to questions suggesting different levels of beryllium exposure. The strata 
included all workers classified as beryllium workers, 10% with no reported exposure, 
10% with minimal reported exposure, and 40% with definite exposure. Participation 
included 863 of the stratified random selection and an additional 32 participants who 
were undergoing clinical evaluation for a total of 895. Medical screening revealed 18 
(2.0%) cases of BeS of which 12 (1.3% of total) had CBD on initial evaluation with an 
additional 3 individuals who developed CBD over the course of the study for a final CBD 
rate of 1.7%. 
A significant increased prevalence of BeS was identified in machinists (4.7%). 
Exposure duration was not significantly different between BeS machinists and non-BeS 
machinists, though BeS machinists reported a significantly longer interval since the first 
beryllium exposure. For non-machinists, there were no significant differences in the 
cumulative years in beryllium exposed jobs between BeS individuals and other 
participants. There did appear to be a consistent pattern of increasing prevalence of BeS 
by self-reported exposure: no exposure (1.5%), minimal exposure (1.1%), intermittent 
exposure (2.6%), and consistent exposure (3.4%). Specific tasks identified with increased 
prevalence of BeS included sawing beryllium (4.7%) and band sawing beryllium (6.0%). 
Based on multivariate logistic regression analysis, the only significant predictors of BeS 
were reported to be “overexposure” to beryllium and exposure to beryllium before 
1970.(8) This study is important in revising the estimated prevalence of BeS at RFETS of 
11.8% (2) exclusively among higher exposed workers at the facility. In addition, the study 
corroborates the risk of BeS for those in low exposure jobs suggesting an increased role 
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of host factors and likely genetics. However, the study is limited in identification of high 
risk jobs and processes due to the low number of cases identified and the resulting 
problem of small subgroups for analysis.(8) 
Stange et al.(67) expanded on the work of Kreiss et al.(8) at the Rocky Flats facility 
with a much larger cohort of employees. The cohort in this study was obtained through 
the voluntary plant medical screening program or Beryllium Health Surveillance Program 
(BHSP) for the time period June 1, 1991 to March 31, 1995. Participation in this program 
was actively offered to all current and former RFETS employees. In this surveillance 
program, a total of 4,397 current and former workers were tested with the BeLPT. The 
initial testing identified 97 new cases of BeS of which 28 had CBD. One or three year 
serial surveillance of the remaining cohort identified an additional 10 cases of BeS of 
which one had CBD. Overall, the BeS prevalence at the end of the study (1995) was 
identified as 2.43% and the CBD prevalence of 0.65%. While the authors did not attempt 
to identify high risk jobs or processes, the analysis suggests that both BeS and CBD 
occurred at a wide variety of exposures and in jobs not previously considered high risk 
such as administrative staff and security guards. The occurrence of cases in buildings and 
jobs with exposures likely below 2.0 µg/m3 continued to suggest that the current OSHA 
permissible exposure limit was not adequate. 
Stange et al. further expanded their work including workers participating in the 
surveillance program through December 31, 1997, as well as an analysis of exposure 
factors.(68) This new study included a total of 5,173 current and former workers with 
verifiable work histories. Initial testing, which overlapped with the previous study (69), 
identified 172 cases of BeS of which 74 had CBD. Three-year serial BeLPT testing 
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identified an additional 63 cases of BeS of which 7 had CBD. The overall rate of BeS and 
CBD was 4.5% including both testing scenarios. For CBD, the estimate was 1.6% which 
is likely low due to the less than 100% participation in medical evaluation procedures by 
those identified as BeS. Significant univariate odds ratios indicating increased risk of BeS 
were identified for individuals who had worked in health physics (2.9, 95% CI: 1.1-7.4), 
as a beryllium machinist (3.0, 95% CI: 2.0-4.8), and in the construction trades (2.4, 95% 
CI: 1.5-4.0). A protective odds ratio of 0.3 (95% CI: 0.1-0.8) was associated with ever 
having worked in security services. The risk of ever having worked in particular 
buildings was also analyzed with significant increased risk associated with ever working 
in buildings 334 (1.8, 95% CI: 1.2-2.5), 444 (1.5, 95% CI: 1.2-2.0), 776 (1.3, 95% CI: 
1.0-1.7), and 865 (1.5, 95% CI: 1.1-2.1). In multivariate logistic models, work as a 
beryllium machinist, work in the construction trades, work in health physics, time since 
hire, and work in building 865 were significant predictors of excess risk. While this 
report suggested a process-related, exposure-response relationship among beryllium 
exposed workers, it also identified cases among employees thought to be only minimally 
exposed. More importantly, there were six cases of BeS and one case of CBD among 
employees hired since 1990 which is important since stringent controls limiting beryllium 
exposure to 0.5 µg/m3 were implemented at that time.(68)  
Sackett et al.(70) examined the prevalences of BeS and CBD among Rocky Flats 
workers hired after the facility had terminated production in 1989. For this report, the 
population consisted of 2,381 workers undergoing medical surveillance between October 
1998 and August 2002. Hire dates were available for 2,342 participants. The cohort 
included 1,152 considered production workers as they were hired prior to 1990 and 1,190 
 19
considered cleanup workers as they were hired after 1990. A total of 13 workers from the 
production era were identified as BeS of which two had confirmed CBD. From the 
cleanup era, a total of seven workers were identified as BeS of which one had confirmed 
CBD. Eleven of the workers identified with BeS did not complete a full clinical 
evaluation for CBD. These numbers translate to a BeS prevalence of 1.2% from the 
production era and 0.6% for the cleanup era, a difference which is not statistically 
significant. This report provides more evidence on the occurrence of BeS in exposure 
situations believed to be well controlled. In addition, the report provides one of the few 
examples where self-reports of accidental beryllium exposure prove to be a significant 
risk factor (OR 3.6, 95% CI: 1.01-12.68). 
Viet et al. (71) conducted a case-control study at the Rocky Flats nuclear weapons 
facility to evaluate the risk of CBD and BeS as it related to various exposure levels. 
Seventy-four cases of BeS, 50 CBD cases, and 124 age and smoking status matched 
controls were enrolled in the study. In order to estimate exposures to study participants, 
the authors constructed a job exposure matrix (JEM). The only exposure information 
available for the majority of the relevant time period consisted of fixed airhead samples 
(FAH) rather than personal samples. These FAH samples were only collected in a single 
building on the Rocky Flats Complex, building 444 which was the beryllium machine 
shop. However, exposure at RFETS was not limited to work in building 444; there were 
several other buildings with beryllium exposure. In order to estimate exposures to 
participants working in other buildings, a relative weighting scheme was established by 
study personnel and verified by plant industrial hygienists. This weighting scheme relied 
on establishing building area factors (BAF) and job factors (JF) relative to the exposure 
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of a machinist in building 444. These exposure factors were used as multipliers to 
establish cumulative exposures for all participants using yearly averages from FAH 
samples in building 444 as the base exposure concentration. For example, a lab 
technician in building 123 had a building exposure factor of 1 and a job exposure factor 
of 2, as compared to a machinist in building 444 with a building exposure factor of 10 
and a job exposure factor of 10. Cumulative exposures were calculated by summing the 
yearly FAH mean concentration times the BAF times the JF over the entire work history 
of a participant. This sum was divided by 100 (10 x 10) to rescale the estimate to µg-
years/m3. A mean exposure was calculated by dividing the cumulative exposure by the 
number of years worked at the facility. 
Based on analyses of the study data, years of employment, cumulative exposure, 
and mean exposure were all greater for CBD cases as compared to matched controls and 
compared to BeS cases. These same factors were consistently in the direction of longer 
duration and higher exposure for BeS cases as compared to controls, but not statistically 
significant. Multiple logistic regression analysis indicated an odds ratio for cumulative 
exposure of 6.9 (95% CI: 2.3 – 20.6) for each tenfold increase in log-transformed 
cumulative exposure and, with an alternative model, an odds ratio of 7.2 (95% CI: 2.2-
23.5) for each tenfold increase in log-transformed average exposure. Neither cumulative 
exposure nor mean exposure were identified as significant predictors of BeS odds.(71)  
Additional analysis dividing the CBD cases and controls into five increasing 
exposure categories showed an increasing proportion of CBD cases with increasing 
exposure, with the exception of the lowest exposure category (0 to 0.03 µg-years/m3) 
suggesting an exposure-response relationship for CBD. A similar trend was not observed 
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for BeS. There is a lengthy analysis on the implications of this study in terms of 
establishing an occupational exposure limit for beryllium. After making several 
assumptions including the differences between FAH samples and personal samples, the 
authors came to the conclusion that, based on their logistic regression model, 
approximately 1 in 200 individuals exposed at 2 µg/m3 would be expected to get CBD.(71) 
This study was the first to clearly show an exposure-response relationship for 
CBD. However, it appears that their model may not account for a large proportion of 
cases observed in the lowest exposure category. Thus, the model and exposure-response 
relationship may not account for an extremely sensitive subpopulation; or alternatively, 
their JEM may not adequately characterize exposures for this subset. In addition, the 
study failed to show any significant exposure-response relationship for BeS. Finally, the 
study provides compelling evidence indicating a higher than traditionally accepted risk (1 
in 1,000) of CBD among workers exposed at levels equivalent to OSHA’s current 
permissible exposure limit.(71) 
 
Beryllium fabrication: private industry 
Newman et al.(72) began medical surveillance at a beryllium machining facility in 
the Southeast U.S. in 1995. Initial testing on the 235 current and newly hired employees 
between 1995 and 1997 identified 15 (6.4%) cases of BeS of which 9 of the 12 
completing medical evaluation were found to have CBD. Biannual testing identified an 
additional 6 BeS individuals of which 5 had CBD. This testing resulting in a point BeS 
prevalence of 9.4%. This study identified BeS in four (6.7%) of the newly hired 
employees. All four of these individuals had worked at the facility for less than three 
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months when tested. Three of the four underwent clinical evaluation and two were found 
to have CBD. This study was the first to identify CBD cases with this short latency and 
with fairly low exposures (median < 0.3 µg/m3). In addition, the study confirmed that 
serial surveillance of exposed workforces will continue to identify new cases of BeS and 
CBD. 
Kelleher et al.(14) conducted a case-control study at the facility reported by 
Newman et al. (72). The cohort for the study consisted of all 235 workers who had 
undergone serial medical surveillance as reported by Newman et al.(72). The authors 
constructed a job exposure matrix for all cases and controls using a combination of work 
history data and exposure measurements. The exposure measurements consisted of 100 
personal impactor samples, four samples per job title, collected in two phases between 
1996 and 1999. The impactor measurements were supplemented with historical and 
current industrial hygiene measurements provided by the facility. While the exposure 
assessment appears somewhat limited in that there were relatively few measurements 
before 1995, analyses in the paper suggest that exposures prior to this period were likely 
similar. The only statistically significant exposure risk factor identified was ever working 
as a machinist with an estimated univariate odds ratio of 4.4 (95% CI: 1.1-17.6). Other 
exposure measures, including total exposure, exposure to particles greater than 6 µm, and 
exposure to particles less than 1 µm, suggest higher exposures (both mean and median) 
among cases as compared to controls. Unfortunately, it appears that significance of the 
exposure factors was limited by the low power of the study. Suggestive evidence of 
higher exposures among cases in addition to the reported 60% of cases with average 
exposures greater than 0.2 µg/m3 suggested an exposure-response relationship that may 
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be confounded by other factors such as particle size and exposure misclassification. 
Interestingly, no cases were identified at exposures less than 0.02 µg/m3. This 
observation may suggest an exposure threshold to prevent sensitization. 
Madl et al.(73) reanalyzed the data from Kelleher et al.(14) to identify exposure 
response relationships and the potential for using the data to establish an occupational 
exposure limit. For this analysis, the authors used a total of five different methods to 
reconstruct exposures for all cases listed in the study by Kelleher et al.(14) along with 
seven additional cases from the facility. The exposure reconstruction methods included 
using the time-weighted average exposure from the highest year exposed and the lifetime 
weighted average exposure using different grouping strategies to account for years with 
sparse or missing data. The authors used a 95th percentile exposure as well as a mean and 
median. The authors argued that the use of an upper bound exposure and the highest year 
of exposure rather than a mean exposure is more appropriate for an immune mediated 
disease and for identifying an appropriate occupational exposure limit. This analysis 
suggested that all cases of BeS and CBD had 95th percentile exposures that exceeded 0.2 
µg/m3. In terms of lifetime weighted average exposures, the new analysis resulted in 
increased estimates of exposure for 11 cases and decreased estimates for 9 cases as 
compared to those reported by Kelleher et al.(14). The data also suggested higher 
exposures for CBD cases as compared to BeS cases. 
Martyny et al.(13) performed particle size selective air sampling at the beryllium 
facility in the Southeast U.S. to identify potential particle size effects that might explain 
the high prevalence of CBD identified among individuals machining beryllium. Cascade 
impactor sampling on five machining processes indicated that more than 50% of the mass 
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of particles generated by machining beryllium were less than 10 µm. The typical mass 
median aerodynamic diameters (MMADs) observed from the five machining processes 
ranged from 0.6 µm to 3.1 µm, with lathe and deburring having the smallest MMAD. 
These exposures result in total respiratory depositions ranging from 46% to 62% of the 
measured exposure. While the size of the exposed cohort limits the power to detect 
associations between specific operations and disease prevalence, it is possible the 
predominance of small particles generated from these machining operations may explain 
the high risk of beryllium machining operations. 
 
Beryllium alloy production and fabrication 
While cases of BeS and CBD at 2% beryllium-copper facilities were reported by 
Balkissoon and Newman(74), as well as by Yoshida et al.(75), full scale epidemiological 
studies were lacking until Shuler et al. conducted a cross-sectional epidemiological study 
at a copper-beryllium alloy facility.(76) This study involved 153 of the 185 current 
employees at the facility and involved a work history interview to describe start and end 
dates of work in specific processes and time spent performing non-routine high exposure 
tasks, such as clean-up and shutdown maintenance. Beryllium air sampling results were 
analyzed for each process including data from 1969 to 2000, with 815 high volume task 
based samples for years before 1995 and 650 personal samples for years beyond 1995.(76) 
 Between 10 and 18 cases were identified at the facility depending on the 
diagnosis criteria including six with CBD (3.9%), 12 with BeS (7.8%), and one with BeS 
who refused clinical evaluation. In evaluating risk factors for BeS/CBD, the authors 
chose to exclude eight BeS cases due to lack of confirmatory BeLPT results between two 
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different laboratories. BeS cases were found to have fewer years since first reported 
beryllium exposure (Mean=1 yr) as compared to non-sensitized workers. CBD cases were 
more likely to have reported skin ulcers or small craters in the skin than non-sensitized 
workers. However, other self-reported skin problems were not more prevalent in either 
BeS or CBD cases. Workers reporting high exposure incidents without respiratory 
protection were more likely to be BeS. There were no differences in participation in non-
routine activities likely to be associated with high beryllium exposures, such as spill 
clean-up and shut-down maintenance among non-sensitized, BeS, or CBD individuals. 
The study did identify work processes with higher prevalences of CBD and BeS 
including rod and wire production and more specifically point and chamfer, wire 
annealing and pickling, and wire drawing. In contrast, work in strip metal production was 
not associated with higher prevalences of BeS or CBD. Exposures at this copper-
beryllium alloy facility were considered to be fairly well controlled with a median plant-
wide exposure of 0.02 µg/m3 for breathing zone samples and 0.09 µg/m3 for general area 
samples between 1969 and 2000. In fact, 99% of all samples were below 2.0 µg/m3 and 
93% were below 0.2 µg/m3. Exposures in rod and wire production were much higher than 
those in strip metal production, with medians of 0.06 µg/m3 and 0.02 µg/m3 respectively. 
In addition, there were significant differences in the upper tails of the exposure 
distributions for rod and wire production processes compared to strip metal production 
processes with upper tolerance limits of 0.68 µg/m3 compared to 0.10 µg/m3. Exposures 
for wire annealing and pickling were clearly higher than for any other process with a 
median of 0.12 µg/m3 and an upper tolerance limit of 2.32 µg/m3.(76) 
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This study was surprising in that BeS/CBD prevalences for the copper beryllium 
facility were similar to disease prevalences observed in facilities with much higher 
documented exposures. Also, the increased prevalence of BeS among employees with 
less than one year of beryllium exposure suggested that cumulative exposure may not be 
a very effective metric in predicting BeS risk. The study clearly demonstrates increased 
BeS/CBD risk from exposure to processes with upper tolerance limits (UTLs) exceeding 
0.2 µg/m3, and possibly lower risks from processes where the upper tolerance limits are 
maintained below 0.2 µg/m3. (76) 
Stanton et al. (18) examined the prevalence of BeS and CBD in copper beryllium 
distribution centers. Among 88 employees from three distribution facilities, one was 
identified with CBD for an overall 1% prevalence. Job specific median air sampling for 
workers at these facilities ranged from 0.01 to 0.07 µg/m3. However, there were several 
processes where UTL exposures exceeded 0.2 µg/m3. 
 
Summary of BeS/CBD epidemiology findings 
While there has been much difficultly establishing a clear exposure-response 
relationship for CBD/BeS, epidemiological studies have consistently identified clear 
“high risk” exposure surrogates. The most consistent findings are those of particular high 
risk processes within an industry. These processes have often been identified as those 
producing smaller particles and sometimes described as having higher exposures than 
other processes within the plant. CBD/BeS has consistently been identified in a small 
percentage of those considered to be at low risk including administrative personnel and 
security guards. BeS/CBD appears to have a variable latency with known cases 
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presenting as early as three months after first exposure and as late as 20+ years after last 
exposure. There is a clear literature documenting cases of BeS/CBD at exposures less 
than the current OSHA Permissible Exposure Level (2 µg/m3). With one exception(71), 
cumulative exposures to beryllium have not been predictive of disease risk. Relative 
exposure assignments involving job specific factors, building specific factors, or self-
reported exposure have been more frequently associated with disease risk. The lack of an 
observed exposure-response may be explained by one of the following alternative 
explanations: 1) the total mass concentration is not relevant to BeS/CBD development; 2) 
past exposure assessment strategies have produced exposure misclassification that 
attenuates the true exposure-response relationship; or 3) there is more than one “true” 
exposure-response relationship for the population and past studies have been unable to 
stratify the population into the appropriate sub-groups. 
 
Beryllium health effects and genetics 
With the lack of clear exposure-response effects identified in the many 
epidemiological studies and the identification of BeS/CBD cases at very low apparent 
exposures, attention shifted to the identification of host factors that may influence the 
effects of beryllium exposure. Based on in vitro immunology studies using cells from 
patients with CBD, Saltini et al. concluded that T-cells are major histocompatibility 
complex (MHC) class II restricted, meaning that T-cells only proliferate in the presence 
of MHC class II molecules on the surface of antigen presenting cells.(77) It has been 
understood for some time that the MHC class II region of the genome is important in 
presentation of antigens for T-Cell recognition.(78) The MHC region of the human 
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genome is the most gene-dense and polymorphic region. The MHC region resides on 
chromosome 6p21.31 with the class II region residing at the centromeric end. The class II 
region codes for HLA-DP, HLA-DQ, and HLA-DR molecules which are heterodimeric 
proteins consisting of α and β chains with the α1 and β1 regions of these chains forming 
the peptide binding region or “groove” important in antigen presentation. As these HLA 
molecules had been associated with susceptibility to autoimmune disorders in other 
studies (79) and similar metal/MHC complexes had been shown to elicit T-Cell reactivity 
with other metals such as nickel and colbalt(80), researchers hypothesized that HLA 
molecules may also be important in the development of BeS/CBD. The working 
hypothesis was that some yet unknown beryllium “moiety”, be it a hapten, antigen, or 
peptide complex, binds to one or more of these HLA molecules on a yet unknown antigen 
presenting cell allowing it to interact with receptor T-cells (TCR) initiating T-Cell 
proliferation and cell-mediated inflammatory processes. 
 
Cross-sectional allele and genotype frequency studies 
To investigate this hypothesis, Richeldi et al.(20) typed the genes of the MHC class 
II region (HLA-DR, -DQ, and –DP) from the DNA of 33 cases of CBD and 44 beryllium 
exposed controls. After preliminary evidence did not show strong associations for the 
HLA-DR and HLA-DQ genes, the researchers focused on the HLA-DP genes finding that 
97% of CBD cases had at least one copy of an HLA-DPB1 encoding allele with a 
glutamic acid substitution at position 69 (E69) of the β chain as compared to just 30% of 
the controls. This was the seminal evidence suggesting that this E69 substitution 
conferred increased susceptibility to CBD. Results of this study have since been verified 
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by many others (Table I-I) showing similar differences in the proportion of E69 encoding 
HLA-DPB1 alleles between cases of BeS/CBD and controls. Overall, the studies have 
found HLA-DPB1 E69 prevalences from 30% to 47% among controls and from 73% to 
97% among CBD cases with the differences highly significant for all the populations 
studied. In terms of BeS, HLA-DPB1 E69 prevalences ranged from 39% to 90% and 
were significantly different from controls in all but one study. 
 
Table I-I – Frequency of HLA-DPB1 E69 alleles by study and diagnosis 
Controls BeS CBD 





Richeldi et al. 1993(20) 44 30% n/a n/a 33 97% 
Richeldi et al. 1997(21) 121 30% n/a n/a 6 83% 
Wang et al. 1999(24) 34 45% n/a n/a 20 95% 
Saltini et al. 2001(19) 93 40% 23 39% 22 73% 
Wang et al. 2001(23) 163 38% 25 88% n/a n/a 
Rossman et al. 2002(25) 82 47% 30 90% 25 84% 
Maier et al. 2003(26) 125 38% 50 85% 104 86% 
McCanlies et al. 2004(27) 727 33% 64 68% 90 82% 
 
HLA-DPB1 allele specific risk 
Other results from these genetic studies suggested differential risk of BeS/CBD 
even among the different HLA-DPB1 E69 alleles and between E69 homozygotes and 
heterozygotes. The HLA-DPB1 gene is very polymorphic with approximately 100 
different alleles. Further, there are approximately 34 allele variants that encode for E69. 
Wang et al.(24) first suggested the importance of the rarer non-*0201 HLA-DPB1 E69 
alleles in conferring increased risk of CBD. Studying 20 CBD cases and 75 beryllium 
exposed controls, Wang et al.(24) found that the CBD predictive value of having any E69 
allele was 0.35 compared to 0.57 for having at least one copy of a non-*0201 E69 allele, 
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and 0.85 for having two copies of E69 alleles. Thus, it appears that the risk of CBD is 
increased for non-*0201 E69 alleles and for additional E69 allele copies. These results 
were later confirmed to apply to BeS as well as CBD in a study comparing 25 BeS cases 
to 163 controls which identified an odds ratio of 7.33 (95% CI: 2.95-18.17) for non-
*0201 E69 alleles and 9.98 (95% CI: 2.78-35.84) for E69 homozygotes.(23)  
The importance of the non-*0201 alleles was confirmed in a study involving 94 
CBD cases, 48 BeS cases, and 115 controls which showed increased prevalence of both 
any E69 allele (BeS:85%, CBD:86%) and non-*0201 E69 alleles (BeS:56%, CBD:63%) 
compared to controls (any E69: 38%, non-*0201: 14%).(26) In this study, while the odds 
ratios for any E69 allele (CBD: 10.0, 95% CI:5.0-20.2, BeS: 9.5, 95% CI: 3.9-22.9) were 
similar to the odds ratios for non-*0201 alleles (CBD: 12.2, 95% CI: 6.1-24.4, BeS: 9.3, 
95% CI:4.2 -20.6), the fact that over 65% of the cases of CBD and BeS were carriers of 
the rarer non-*0201 allele confirms its importance.(26) This study also confirmed the 
importance of homozygosity, especially for CBD, with an odds ratio of 19.4 (95% CI: 
4.4-84.5) for CBD and 8.8 (95% CI: 2.0-39.5) among E69 homozygotes.(26) Another 
study of similar size (90 CBD, 64 BeS, and 727 controls) showed a similar increased 
prevalence for E69 homozygotes with odds ratios of 24.3 (95% CI: 10.8-54.6) for CBD 
and 6.4 (95% CI: 2.1-19.7) for BeS as compared to E69 heterozygotes with odds ratios of 
9.4 (95% CI: 5.4-16.6) for CBD and 3.3 (95% CI: 1.8-5.9) for BeS.(27) 
 
Functional significance of HLA-DPB1 E69 
With the discovery of the increased susceptibility to BeS and CBD among carriers 
of the HLA-DPB1 E69 variant, several studies were initiated to determine whether this 
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variant is just a “marker” of susceptibility to beryllium-related health effects, or whether 
it is functionally significant. Benchtop immunology studies quickly identified its 
functional significance, as antibodies to HLA-DPB1 can block the proliferative response 
to beryllium stimulated T-Cells and reduce cytokine production (TNF-α, INF-γ) which 
are a class of inflammatory markers important in granulomatous lung disease.(30, 81, 82) It 
has also been identified that among CBD patients, the E69 marker is clinically important 
with increased gas exchange abnormalities among those with the E69 marker and 
significantly reduced forced vital capacity among E69 homozygotes.(26) Molecular 
modeling of the HLA-DP β chain adds support to the hypothesis that E69 is involved in 
the antigen binding process predicting the location of E69 in an influential position 
within the antigen binding groove.(30)  
Molecular modeling has also led to new hypotheses about the risks conferred by 
the *0201 alleles as compared to the non-*0201 alleles. Snyder et al.(32) generated three-
dimensional models of HLA-DP proteins encoded by the *0201 and a subset of the non-
*0201 alleles. From these models, the electrostatic potential of the antigen binding 
groove encoded by each of the alleles was calculated. These calculations identified 
substitutions by charged amino acid residues such as aspartic acid (D), glutamic acid (E), 
arginine (R), and lysine (K) at positions β55, β56, β69, β84, and β85 affect the 
electrostatic potential at the antigen or peptide binding groove. It was identified that 
substitutions in non-*0201 E69 alleles increased the electrostatic potential of the encoded 
β-chain as compared to *0201 alleles. Analysis of pooled epidemiological data from 
previous studies, including allele specific typing and case status for 67 CBD cases, 78 
BeS cases, and 338 controls using the electrostatic potential on the β-chain encoded by 
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the allele as a continuous covariate, identified a significant log-linear relationship 
between the magnitude of the electrostatic charge and the log odds of CBD and BeS with 
correlation coefficients of -0.85 and -0.67 respectively for CBD and BeS. This very 
intriguing finding suggests that the risk of CBD/BeS is inversely proportional to the 
charge on the β-chain of the HLA-DP molecule which greatly strengthens the functional 
significance of the HLA-DPB1 epidemiological findings. 
Snyder et al. 2007(31) further extended the hypotheses regarding the effects of 
electrostatic charge and allele specific risk. Based on the previous study, researchers 
identified that the charge on most of the E69 encoding alleles ranged from -7 to -9 with 
most of the non-*0201 E69 alleles at -9.(32) In extending the hypothesis of increased 
BeS/CBD risk with decreasing charge, researchers surmised that E69 alleles with a -9 
charge confer increased risk of CBD and an increased risk of progressing to CBD among 
those with BeS as compared to those E69 alleles with a -7 charge. In contrast, the 
researchers surmised that risk of BeS was approximately equal for E69 alleles with either 
a -7 or -9 charge. To evaluate these hypotheses, the researchers analyzed allele specific 
typing data and case status on 84 cases of CBD, 72 cases of BeS, and 698 controls. It was 
identified that individuals with a -9 charge on their E69 allele had a nearly 3 fold 
increased risk of developing CBD or progressing to CBD if previously diagnosed with 
BeS as compared to those with a -7 charge on their E69 allele. In contrast, there was no 
difference in risk for developing BeS comparing the -9 charged E69 alleles to the -7 
charged alleles. By adding the charges for an individual’s two alleles, the study also 
identified a trend showing that increased numbers of HLA molecules encoded with a high 
negative charge results in increased CBD risk, thereby confirming the higher CBD risk 
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identified in E69 homozygotes and further suggesting additional increased risk from two 
copies of high negative charge encoding E69 alleles.  
 
Summary of genetic findings 
Evidence from genetic studies have allowed the identification of at least a portion 
(if not the majority) of the BeS/CBD susceptible sub-population. It is clear that carriers of 
the HLA-DPB1 E69 variant are at higher risk of both BeS and CBD when exposed to 
beryllium. This variant appears to be functional in the antigen presentation phase of the 
immune response to beryllium.  It also appears that specific non-*0201 E69 encoding 
alleles confer increased risk compared to the more common *0201 alleles. This increased 
risk may be explained by the higher negative electrostatic potential imparted to the 
antigen binding groove by amino acid substitutions encoded by these E69 alleles. 
Increasing numbers of E69 containing HLA-DP molecules in E69 homozygotes appears 
to further increase BeS/CBD risk. However, on the basis of these studies, between 3% 
and 27% of CBD cases do not have the HLA-DPB1 E69 variant which clearly indicates 
that there are other important factors, both exposure and host, to be studied. Recently, 
much of this work has focused on HLA-DR, HLA-DQ, and gene polymorphisms 
associated with pulmonary inflammation such as TNF-308A. However, these studies are 
beyond the scope of this dissertation. 
 
Gene-exposure interaction 
With evidence suggesting that less than 20% of exposed individuals get CBD 
even at high modern day exposure levels and conversely suggesting that a smaller 
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number of individuals seem to be at risk for CBD even at extremely low exposures, it is 
clear that both exposure and host factors play a role in CBD pathogenesis. Only one study 
to date has evaluated the combined effect of exposure and genetics in CBD. Richeldi et 
al.(21) studied a population of 127 workers from the Tucson beryllium ceramics facility 
including six CBD cases and two BeS cases. As a surrogate for exposure, the researchers 
separated the cohort into those who had ever performed machining operations (exposures 
estimated at approximately 0.9 µg/m3) and those who had never performed machining 
operations. The prevalence of CBD among HLA-DPB1 E69 negative individuals was 
1/86 (1.2%) compared to 5/41 (12.2%) among those with at least one E69 encoding 
allele. Comparing case prevalence to exposure, the researchers found the prevalence 
among those who had ever been a machinist was 5/47 (10.6%) compared to 1/80 among 
those never assigned to machining. Of the six CBD cases, only one did not have a history 
of machining exposures. This individual was HLA-DPB1 E69 positive. In multivariate 
analysis, significant odds ratios were identified for both high exposure (OR 10.1, 95% CI: 
1.1-93.7) and for carriers of the HLA-DPB1 E69 variant (OR 11.8, 95% CI: 1.3-108.8). 
This seminal study in gene-environment interactions has important implications in that it 
suggests a similar magnitude of increased CBD risk from either high exposure or genetic 
susceptibility. Unfortunately, the study with only six cases did not have sufficient power 
to evaluate the combined effect of genetics and exposure. In addition, the study has 
limitations due to the small population size and the lack of more detailed exposure 
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EXPOSURE AND GENETICS IN BERYLLIUM SENSITIZATION AND CHRONIC 
BERYLLIUM DISEASE: A CASE-CONTROL STUDY AT ROCKY FLATS 
ENVIRONMENTAL TECHNOLOGY SITE 
Abstract 
The development of beryllium sensitization (BeS) and chronic beryllium disease 
(CBD) are determined by at least one well-studied host genetic factor, a glutamic acid 
residue at position 69 (E69) of the HLA-DPB1 gene, as well as exposure to beryllium. 
However, the nature of the relationship between exposure and carriage of the E69 
genotype has not been well studied. The goal of this study was to define the relationship 
between beryllium exposure and E69 for CBD and BeS. 
Former workers (n=386) from a decommissioned U.S. nuclear weapons 
production facility, Rocky Flats Environmental Technology Site (RFETS, Arvada, CO) 
were enrolled into a case-control study including 70 with BeS, 61 with CBD, and 255 
controls. HLA-DPB1 genotypes were determined by PCR-SSP. Beryllium exposures 
were reconstructed using a task-based exposure matrix developed from worker interviews 
and historical beryllium exposure measurements. 
CBD cases had significantly higher cumulative exposures (median=1.46 µg/m3-
years) and lifetime weighted average exposures (median=0.07 µg/m3) than either BeS 
cases (median=0.11 µg/m3-years, p=0.001 and 0.01 µg/m3, p=0.001) or controls 
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(median=0.39 µg/m3-years, p=0.018 and 0.03 µg/m3, p =0.008). Conversely, BeS cases 
had lower cumulative exposures (median=0.11 µg/m3-years) than controls (median=0.39 
µg/m3-years, p=0.034) and a trend toward lower lifetime weighted average exposure 
(median=0.01 µg/m3 vs. 0.03 µg/m3, p=0.064). The E69+ genotype frequency was 
significantly higher for both BeS cases (92.9%, p < 0.001) and CBD cases (83.6%, p < 
0.001) as compared to controls (38.0%). Analyses that jointly considered E69 genotype 
and Be exposure showed that carriage of any HLA-DPB1 E69 variant conferred about an 
eight-fold increased odds for CBD while each unit increase in lifetime weighted average 
Be exposure increased odds approximately two-fold. Compared to HLA-DPB1 E69 
negative genotypes, carriage of a single HLA-DPB1 *02 allele conferred a 12-fold 
increased odds for BeS (OR: 12.01, 95% CI: 4.28-33.71) and a three-fold increased odds 
for CBD (OR: 3.46, 95% CI: 1.42-8.43). A single copy of a rarer non-*02 E69 allele 
conferred a 30-fold increased odds for BeS (OR: 29.54, 95% CI: 10.33-84.53) and a 
nearly 12-fold increased odds for CBD (OR: 11.97 95% CI: 5.12-28.00) and two E69 
allele copies conferred a 55-fold increased odds for BeS (OR: 55.68, 95% CI: 14.80-
209.40) and a 22-fold increased odds for CBD (OR: 22.54, 95% CI: 7.00-72.62).  
HLA-DPB1 E69 carriage and Be exposure each contribute individually and 
together contribute additively to the odds of CBD. In contrast, while HLA-DBB1 E69 
was identified as a significant predictor of BeS, exposure measures were not significant. 
The increased odds for both CBD and BeS conferred by carriage of HLA-DPB1 E69 
alleles appears to be differentially distributed by genotype with carriers of rarer HLA-
DPB1 non-*02 E69 alleles and HLA-DPB1 E69 homozygotes at higher odds than those 
with the more common HLA-DPB1 *02 genotypes. 
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Introduction 
Beryllium is a low-density metal with unique properties including high specific 
stiffness, high thermal conductivity, corrosion resistance, dimensional stability, and the 
ability to reflect neutrons. As a result of these properties, nearly all U.S. nuclear weapons 
have utilized components fabricated from beryllium. In manufacturing nuclear weapons, 
workers at U.S. and international facilities have cast, machined, polished, pressed, 
extruded, welded, and plated beryllium components. A subset of workers exposed to 
aerosols generated by the fabrication of beryllium containing materials at nuclear 
weapons sites and other manufacturing facilities have developed beryllium sensitization 
(BeS) and chronic beryllium disease (CBD).  BeS is the demonstration of a cell mediated 
immune response to beryllium. Specifically, beryllium stimulates T-cell proliferation 
which occurs via presentation of an unknown beryllium antigen by Human Leukocyte 
Antigen (HLA) class II molecules on antigen presenting cells (APCs) and is 
demonstrated clinically with the beryllium lymphocyte proliferation test (BeLPT).(1-4) In 
some individuals, BeS progresses to CBD, a progressive lung disease characterized by 
non-caseating granulomas.(5, 6) Progression from BeS to CBD is characterized by a Th1 
mediated immune response with accumulation of Be-specific T cells and production of 
IFN-γ, IL-2 and TNF-α in the lung.(7-10) This immune response results in granulomatous 
inflammation, and eventually fibrosis.  
While the prevalence of BeS and CBD appears to vary depending on the 
workforce studied and other beryllium exposure characteristics, prevalences of up to 15% 
for BeS and 8% for CBD have been reported in previous studies of beryllium exposed 
workforces.(2, 11) The Rocky Flats facility or the Rocky Flats Environmental Technology 
 82
Site (RFETS) is one of the largest and best studied beryllium-exposed workforces, 
located approximately 20 miles west of Denver, CO. Since the late 1950s, workers at this 
former nuclear weapons facility performed a number of beryllium fabrication operations 
on a production scale including casting, machining, and welding. A cross-sectional study 
at RFETS in the late 1980s, limited to employees identified as having significant 
beryllium exposure (beryllium machinists), identified prevalences of 11.8% for BeS and 
7.8% for CBD among the 51 workers studied.(2) Later studies expanding the study 
population identified estimated prevalences ranging from 2.0% to 4.5% for BeS and 
0.65% to 1.3% for CBD.(12-14) These later studies also identified specific risk factors for 
BeS including machining beryllium (12, 14), work in construction trades (14), and work in 
specific buildings at RFETS(14).  In general, at RFETS and other facilities, higher 
beryllium exposures have been associated with higher rates of BeS and CBD. However, 
the nature of the exposure-response relationship does not appear to be linear with reports 
of both BeS and CBD consistently documented in individuals with low exposure jobs, 
such as administrative personnel, security guards, and warehouse workers(12, 15, 16). The 
strongest evidence for an exposure-response relationship was identified in a matched 
case-control study conducted at RFETS in the early 1990s which showed a nearly seven-
fold increased odds for CBD for each ten-fold increase in log transformed cumulative 
beryllium exposure.(17) However, neither cumulative nor mean beryllium exposure were 
identified as significant predictors for BeS odds in this study.(17) Differences in exposure 
characteristics have been proposed for the lack of a linear exposure-response identified in 
most other studies, including different physical or chemical forms of beryllium(18), 
exposure to smaller particle sizes (19-22), and the failure to account for dermal exposure to 
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beryllium(23-25). Recent studies suggest that host factors strongly contribute to the risk of 
BeS and CBD among workers exposed to beryllium. 
In a seminal paper, Richeldi et al.(26) demonstrated that HLA-DPB1 alleles with a 
glutamatic acid at position 69 of the β chain (E69) were overrepresented in CBD cases 
(97%, n=33) compared to beryllium exposed controls (30%, n=44). More recent studies, 
including from our group, have verified these results showing increased frequencies of 
E69 in cases of not only CBD (61-97%), but also BeS (39-90%), compared to controls 
(30-47%).(27-34) It has been suggested that differential risk of BeS and CBD is conferred 
by different E69 containing alleles possibly due to alterations in the encoded antigen 
binding groove for beryllium produced by different amino acid substitutions. 
Specifically, the less common or rarer non-*02 E69 alleles have been associated with 
increased odds for CBD and BeS as compared to the *02 E69 alleles.(28, 31, 34) Copy 
number of E69 encoding alleles may also be important with E69 homozygotes 
demonstrating greater odds of BeS and CBD as compared to heterozygotes.(28, 31, 32, 34) 
Immunology studies have verified the functional significance of E69 to the beryllium 
immune response as antibodies to HLA-DP block beryllium stimulated proliferation and 
Th1 cytokine production and mutant fibroblasts without the E69 cannot stimulate 
proliferation or cytokine from T cells.(35-37) Molecular modeling of the HLA-DP β chain 
has demonstrated that E69 is located in the antigen binding groove allowing it to directly 
interact with a putative beryllium antigen.(35) Computational modeling has also suggested 
that the risk of BeS and CBD may be inversely proportional to the electrostatic potential 
of the β-chain of the HLP-DP molecule with most of the non-*02 E69 alleles having a 
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greater negative charge and increased risk of BeS and CBD as compared to *02 E69 
alleles.(38, 39) 
Studies evaluating the combination of genetic and exposure factors on the odds of 
BeS and CBD are limited. In one study, work as a machinist (OR 10.1, 95% CI: 1.1-
93.7), a surrogate for high beryllium exposure, and carriage of HLA-DPB1 E69 (OR 
11.8, 95% CI: 1.3-108.8) were each individually associated with increased odds of CBD 
in a population of 127 workers in the primary beryllium industry, but based on only six 
CBD cases.(27) The larger study presented in Chapter 2 of this dissertation evaluated 
nuclear workers (n=181) including 35 with BeS and 19 with CBD, and also demonstrated 
increased odds of BeS and CBD associated with E69 carriage (OR 7.41, 95% CI: 2.31-
23.75) and for those with reconstructed exposures above the median (OR 5.13, 95% CI: 
1.59-16.57).  In this larger study, the combination of E69 carriage and high exposure 
resulted in a additive odds (OR 38.0, 95% CI: 6.02 – 240). Neither of these studies used 
industrial hygiene measurements to define exposure, nor did they have sufficient power 
to evaluate the effects of E69 copy number or the odds of specific E69 alleles. 
Based on the above studies, we hypothesized that HLA-DPB1 E69 homozygosity 
and carriage of non-*02 E69 alleles both in combination with higher exposure to 
beryllium would confer increased odds of BeS and CBD.  To address this hypothesis, we 
undertook a case-control study of a large population of nuclear weapons production 
workers who were involved in fabrication of beryllium components. In addition to 
addressing HLA-DPB1 E69 status (including copy number and specific E69 alleles), in 
this study, we used industrial hygiene exposure data and worker interviews to reconstruct 
beryllium exposures to address the gene-exposure relationship for BeS and CBD in the 
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largest single workforce cohort of BeS and CBD cases. The aims of the study were to: 1) 
verify the additive odds for BeS and CBD conferred by E69 and beryllium exposure; 2) 
define whether E69 homozygotes and carriage of specific E69 alleles impact the odds of 
BeS and CBD after adjusting for beryllium exposure, and; 3) define beryllium exposure 





The current investigation was conducted among workers from Rocky Flats 
Environmental Technology Site (RFETS). This facility opened in 1951 for the express 
purpose of processing and machining plutonium, uranium, and other materials into a 
detonator or “trigger” for nuclear weapons. A change in weapons design in the late 
1950’s resulted in the wide-scale use of beryllium in components manufactured at 
RFETS.(40) Beryllium components were cast, pressed, rolled, machined, treated (plated, 
coated, etc.), and joined on a production scale at the facility. In addition, research and 
development operations at RFETS included extensive metallurgical testing, as well as the 
development of new methods for forming, joining, and machining beryllium.  The best 
estimates indicated that approximately 15,063 production workers and 3,250 construction 
workers were employed at RFETS during the life of the plant.(41) At least 7,820 of these 
workers were part of a serial medical surveillance program which included testing with 
the BeLPT and resulted in at least 117 individuals diagnosed with CBD and 184 with 
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BeS.(42) In 1993, the site’s mission changed to cleanup and closure with the official 
decommissioning and closure of the facility in 2005. 
 
Study recruitment and design 
All workers ever working at RFETS and participating in beryllium medical surveillance 
were eligible to participate in the study. These workers were recruited using three 
methods: 1) mailings to all workers potentially exposed to radiation or beryllium 
informing them of their eligibility for participation in free medical screening at National 
Jewish Health (NJH); 2) presentations at the RFETS beryllium support group which 
includes some of the cases of BeS and CBD; 3) clinical recruitment of cases of BeS and 
CBD through the NJH Occupational Medicine clinic. 
Cases were defined as BeS if the individual had two or more abnormal blood 
BeLPT results and/or an abnormal bronchoalveolar lavage (BAL) BeLPT. Cases of BeS 
had undergone a medical evaluation and had no evidence of CBD (confirmed BeS) or had 
not undergone a complete medical evaluation to exclude CBD (unconfirmed BeS). CBD 
cases were required to have evidence of BeS along with either: 1) pathological evidence 
of granulomatous inflammation on biopsy; or 2) both an abnormal BAL BeLPT and 
greater than 15% lymphocytes in BAL fluid. Individuals who had worked at the RFETS 
facility and had at least two normal BeLPTs with at least one in the last five years, along 
with no abnormal blood BeLPTs were classified as controls. 
A case-control study was undertaken with controls frequency matched 
approximately two to one to cases based on gender, race, and decade of hire at RFETS to 
allow for similar exposure potential between cases and controls. The study protocol was 
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reviewed and approved by the National Jewish Health Institutional Review Board. 
Written informed consent was obtained from each study participant. Following consent 
administration, all subjects underwent a blood draw to obtain DNA, signed a HIPAA 
release to obtain medical surveillance data, and were interviewed using a standardized 
work history/exposure questionnaire. 
 
DNA extraction and HLA-DPB1 genotyping 
Genomic DNA was extracted from peripheral blood and DNA was extracted 
using the Wizard Genomic Purification kit (Promega, Madison, WI). Genotyping was 
performed using sequence specific primer-polymerase chain reaction (SSP-PCR) for 
HLA-DPB1 as described by Gilchrist(43). Briefly, combinations of forward and reverse 
allele specific primers were used to genotype each DNA strand, cis and trans, allowing 
determination of alleles for HLA-DPB1. The HLA-DPB1 typing plates were designed to 
detect all alleles found at greater than or equal to 1% in Caucasian populations.  
 
Exposure questionnaire 
A work history/exposure questionnaire was developed using information from 
focus groups of RFETS workers. This questionnaire was administered by one of four 
trained interviewers, with industrial hygiene or exposure assessment experience, using an 
interview script and work history for each participant to establish start and end dates of 
each work assignment. Participants were asked to verify the start and end dates for each 
job assignment (i.e., machinist, chemical operator, electrician, etc.) along with an 
estimate of the average number of hours worked per week in the job. Calendar time and 
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hours worked were used to establish an exposure time. The specific tasks (i.e., lathe, 
grind, plating, cleaning, etc.) performed for each job assignment were also recorded. 
Participants were asked to categorize each task in into one of seven exposure categories 
listed in order of decreasing qualitative exposure: 1) directly altering a beryllium part; 2) 
contact with beryllium waste materials; 3) contact with finished and cleaned beryllium 
parts; 4) work within 5 feet of a beryllium operation with no direct beryllium contact; 5) 
work in the same room as a beryllium operation with no direct beryllium contact; 6) work 
in the same building as a beryllium operation with no direct beryllium contact; or 7) no 
known beryllium exposure. For each of the tasks, the participant provided a percentage of 
time spent performing the task and a percentage of time spent performing the task with 
beryllium.  
 
Task exposure estimates 
From the exposure questionnaires, a total of 50 unique combinations of exposure 
category and task were identified (Table III-I) consisting of 27 with direct beryllium 
exposure involving direct work with a beryllium part or with beryllium waste materials 
and 23 with indirect beryllium exposure where there was no direct work with beryllium 
or beryllium waste materials, but instead proximity to a beryllium operation. Based on 
published information(17, 44, 45) and personal knowledge about beryllium production at 
RFETS, the 50 combinations were separated into one to three time periods of similar 
exposure based on installed controls and plant practices as shown in Table III-I. For each 
of the unique combinations of exposure type, task, and time period that involved direct 
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exposure to beryllium, the data sources listed below were searched for industrial hygiene 
data on the specific task or closely related tasks: 
1. RFETS historical data consisted of approximately 1,800 samples compiled by 
researchers in the late 1990’s constructing a multiple chemical job exposure 
matrix(46) in addition to a database of over 1,100 beryllium samples compiled 
from primary sources for this study. The data spans the years 1954 to 1996 and 
represents most of the major tasks at Rocky Flats. All of the data prior to 1984 
was derived from high-volume, short-term air samples. Post-1984 data were 
derived from full-shift breathing zone samples of mostly machining tasks with a 
few shorter term samples of casting tasks.  
2. RFETS machining operations pre- and post-control sampling report(44) 
described an analysis of 695 personal breathing zone samples collected from 
machinists in the primary beryllium machine shop at RFETS. The purpose of this 
report was to quantify average exposures for RFETS machinists before and after 
the installation of an upgraded low-volume, high-velocity ventilation system in 
1986. 
3. RFETS cleanup era data consisted of beryllium sampling data from the clean-
up, demolition, and decontamination of the facility’s two major beryllium related 
buildings (444 and 865). These data consisted of over 8,000 personal samples 
spanning the years 1999 to 2008 and provided unparalleled data on exposures for 
maintenance and cleaning tasks using modern control measures. These data were 
provided to study investigators after removal of all personally identifiable 
information by colleagues at Oak Ridge Associated Universities.  
 90
4. Published RFETS summary data were available from studies by Barnard et 
al.(45) and Viet et al.(17) including a summary analysis of a random sample of over 
12,000 of the 500,000 high-volume, fixed airhead samples collected between 
1960 and 1988 in the main RFETS beryllium machine shop. These data likely 
provide the best estimate of exposure for workers indirectly exposed to beryllium 
from proximity to beryllium machining tasks. 
5. Other Department of Energy site data consisted of beryllium sampling data 
from the Y-12 facility in Oak Ridge, TN where similar beryllium tasks were 
conducted. This limited dataset contains approximately 1,800 personal breathing 
zone samples on a limited number of tasks and provides relevant beryllium 
exposure data for metallurgy, laboratory analysis, inspection, and plasma spray 
tasks. 
6. International data from another atomic weapons facility were available for a 
facility in Cardiff, Wales which performed similar operations to RFETS from a 
study by Johnson et al.(47). These data consisted of yearly summaries of 217,000 
personal beryllium samples by job task. While many of the job tasks at the Cardiff 
facility used different controls than similar job tasks at RFETS during the early 
years, the data were useful for establishing exposure estimates for specific tasks 
including casting after 1986, beryllium inspection, laboratory analysis, and 
maintenance. 
7. Beryllium precision machine shop data consisted of beryllium a sampling 
dataset from a facility the Southeast U.S. spanning the years 1980 to 2008 with 
more than 6,340 samples of machining, inspection, deburring, administrative, and 
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maintenance tasks that were compiled by the authors. Many of the job tasks at this 
facility were similar to those performed at RFETS. In fact, this facility fabricated 
some of the same beryllium components as were manufactured at RFETS. 
Analyses of portions of this dataset have been published by Kelleher et al.(22) and 
Madl et al.(48). 
8. Other relevant beryllium facility data were available through published 
literature and government documents. Exposure data from facilities machining 
beryllium copper were available from public comments to the OSHA Docket for 
pending legislation(49). Data on billet cutting in the primary beryllium industry 
were also available through the OSHA Docket(50). 
An arithmetic mean of the available exposure measurements was calculated for each 
combination of exposure type, task, and time period using the measurements from 
available data sources that were considered closest in time period and task composition 
based on the judgment of the authors. The source of the data used for each task is listed in 
Table III-I. The arithmetic mean was calculated using one of three methods depending on 
the data available: 1) If less than six measurements were available or the data were 
determined to follow a normal distribution based on the D’Agostino-Pearson omnibus 
normality test, a simple average was calculated. 2) With six or more lognormally 
distributed measurements, the minimum variance unbiased estimate of the arithmetic 
mean was calculated using methods outlined in Gilbert (51) when no non-detectable values 
were present in the dataset, or using a maximum likelihood estimation method as 
described by Finkelstein and Verma (52) when there were non-detectable values in the 
dataset. 3) When only median values from summary data were available, an arithmetic 
 92
mean was calculated using the relationships outlined in Strom and Stansbury (53) 
assuming the data followed a lognormal distribution and that the geometric standard 
deviation was 3 which is within the range described by Wambach (54) for frequently 
monitored high hazard agents. The arithmetic mean was chosen as an appropriate 
summary measure for each exposure type, task, and time period combination to allow the 
calculation of cumulative and lifetime weighted average concentrations.(55) 
As very little relevant data were available for indirect beryllium exposure tasks, we 
used a conservative method for assigning average exposures to these tasks. Reported 
indirect exposures within 5 ft. of a beryllium task were assigned an average of 50% of the 
task, those in the same room 10% of the task, and those in the same building 1% of the 
task. While there are limited data to validate this method, Barnard et al.(45) identified that 
personal breathing zone samples were on average six to seven times greater than fixed 
airhead monitors from the same area and time period. This suggests that using a 50% 
reduction for exposures within 5 feet of direct beryllium operations is likely conservative. 
Approximately 12% of the indirect exposure tasks reported in the exposure 
questionnaires could not be linked to specific direct exposure tasks. For these situations, 
an average estimated from other indirect exposure tasks weighted by the amount of time 
the entire cohort spent in these tasks was used. 
 
Participant exposure assessment 
To summarize participants’ varying beryllium exposure work histories, 
cumulative and lifetime weighted mean beryllium exposure were calculated in units of 
µg/m3-years or µg/m3, respectively. First, job specific exposure estimates were 
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determined for each individual by multiplying the exposure estimate for the combination 
of exposure category, task, and time period in µg/m3 by the percent of time worked with 
beryllium in that time period, the percent of time performing the task, the number of 
years spent in the job, and the average number of work hours per week divided by 40 
hours.  Cumulative exposure was calculated by summing all of the job specific exposures 
for an individual. Lifetime weighted mean exposure was calculated by dividing the 
cumulative exposure by the total number of years worked. For each participant, beryllium 
exposure and work time were included over a work history until the date of employment 
termination at RFETS or until the date of BeS or CBD diagnosis for the cases, whichever 
came first. The maximum task-based exposure in µg/m3 for any exposure time period 
was used as a surrogate of short-term high exposure regardless of exposure time. Other 
exposure metrics used in our analyses were determined directly from the exposure 
questionnaires including the highest reported exposure category (e.g., directly altering 
beryllium part, contact with beryllium waste materials, etc.), the year of first beryllium 
exposure, work with beryllium oxide or as a beryllium machinist, and the percent of an 
individual’s work time at RFETS spent directly or indirectly exposed to beryllium. 
 
Statistical analysis 
We used SAS v. 9.1 (SAS Institute, Inc., Cary, NC) for statistical analyses. Univariate 
tests of association between categorical variables were performed using χ2 and Fisher’s 
exact tests. P-values from categorical analyses were corrected for multiple comparisons 
using the Bonferroni method. Due to skewed distributions, continuous variables were 
compared across the three groups (controls, BeS, and CBD) using the Kruskal-Wallis test 
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followed by pair-wise comparisons using the Mann-Whitney test when significant (p ≤ 
0.05). Unconditional logistic regression was used to model disease state as a function of 
multiple predictors, including gene and environment variables. Two strategies for 
inclusion of genetic variables in logistic regression models were used: 1) carriage of any 
E69 allele, and 2) an allele specific risk model. The allele specific risk model used a set 
of classification variables coded as: 1) carriage of only E69 negative alleles; 2) carriage 
of a single copy of an *02 allele along with an E69 negative allele; 3) carriage of single 
E69 positive non-*02 allele along with an E69 negative allele; or 4) carriage of two E69 
allele copies, one *02 allele and one E69 positive non-*02 allele. For this model, the first 
variable (E69-) was modeled as the reference. Also in this model, E69 homozygotes with 
two copies of either *02 alleles (n=10) or E69 positive non-*02 (n=3) were excluded 
from the analysis due to insufficient numbers to classify these genotypes in separate 
categories. Cumulative and lifetime weighted mean exposure variables were included in 
logistic regression models as continuous covariates both to reduce the occurrence of 
sparse classification cells and to increase power. A purposeful model building strategy(56) 
was used wherein all independent variables with univariate p-values less than 0.25 were 
evaluated in multivariate models which included one genetic variable specifying E69 
status or genotype and one continuous exposure variable. A significance level of 0.05 
was required for a variable to remain in the model. First-order interactions with 
significance levels at or below 0.1 were included in the final model. All demographic 
variables were tested in the final model for confounding and included in the model when 
their presence resulted in a at least a 10% change in any of the estimated regression 
coefficients. Based on significant differences in exposure between CBD and BeS cases, 
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as well as between CBD cases and controls, CBD and BeS were modeled as separate 
outcomes. We included the following E69 genetic variables in our final logistic 
regression models: 1) carriage of only E69 negative alleles; 2) carriage of a single copy 
of an *02 allele along with an E69 negative allele; 3) carriage of single E69 positive non-
*02 allele along with an E69 negative allele; or 4) carriage of two E69 allele copies, one 
*02 allele and one E69 positive non-*02 allele. E69 homozygotes with two copies of 
either *02 alleles or E69 positive non-*02 alleles were excluded from the analysis. 
Candidate exposure variables for logistic regression models included lifetime weighted 
average exposure, cumulative exposure, maximum task-based exposure, highest reported 
exposure category, year of first beryllium exposure, work with beryllium oxide or as a 





A total of 399 individuals were enrolled in this study. Thirteen subjects were 
excluded for the following reasons: five because they did not meet our criteria for 
diagnosis of CBD or BeS (two with only one abnormal BeLPT, one diagnosed with 
sarcoidosis without abnormal BeLPTs, two with insufficient medical information to 
provide an accurate diagnosis), four with either a diagnosis of BeS or CBD before their 
hire date at RFETS or with long-term beryllium exposure at a facility other than RFETS, 
and four whose DNA was unavailable for genotyping. The final cohort consisted of 386 
former RFETS workers including 255 controls with potential beryllium exposure, 61 
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subjects with CBD, 53 subjects with confirmed BeS, and 17 individuals who were 
classified as unconfirmed BeS due to two abnormal BeLPTs, but who had not undergone 
a bronchoscopy to rule out CBD. 
 
Demographic characteristics 
As shown in Table III-II, there were no significant differences in age, year of hire 
at RFETS, and the number of years worked at RFETS among the three groups. The 
cohort was predominately male (88.3%) consistent with the traditionally male dominated 
workforce at RFETS. However, there were proportionately more female cases of BeS 
(n=15, 21.4%) compared to controls (n=25, 9.8%, p=0.013) and CBD cases (n=5, 8.2%, 
p=0.050). While participants were predominately Caucasian (97.7%) and non-Hispanic 
(93.8%), there was a significantly higher proportion of African-American CBD cases 
(n=4, 6.6%) compared to controls (n=3, 1.2%, p=0.028). Hispanics were over-represented 
among BeS cases (n=8, 11.4%) compared to controls (n=11, 4.3%, p=0.039). A trend for 
increased smoking in BeS cases was apparent, with BeS cases more likely to be current 
smokers (n=8, 11.4%) compared to controls (n=13, 5.1%, p=0.094) and CBD cases (n=2, 
3.3%, p=0.104). BeS cases also worked fewer years at the facility (median=12.6) 
compared to controls (median=15.0, p=0.020). Among those classified as BeS, there 
were no differences in age, gender, race, ethnicity, smoking status, year of hire at RFETS, 
or years spent working at RFETS between those with confirmed BeS and those with 
unconfirmed BeS (data not shown). 
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Exposure characteristics 
Qualitative exposure characteristics 
Qualitative self-reported exposure characteristics are shown in Table III-III 
comparing cases and controls. Overall, 86.3% of the cohort reported direct or indirect 
exposure to beryllium and 16.9% of the typical participants’ time was spent working in 
jobs with direct or indirect beryllium exposure. Only 12.4% of the participants had ever 
worked as a beryllium machinist. CBD cases spent a greater percentage of their time 
directly exposed to beryllium (median=4.3%) as compared to BeS cases (median=0%, 
p=0.009) and while the comparison was not significant compared to controls, a trend was 
apparent (median=1.3%, p=0.061). In addition, CBD cases were more likely to report 
direct exposure to beryllium (68.9%) as compared to BeS cases (45.7%, p=0.026). 
Interestingly, BeS cases were less likely than controls to report direct exposure to 
beryllium (45.7% vs. 62.3%, p=0.039), and there was a trend suggesting BeS cases were 
more likely to report “no known exposure to beryllium” compared to controls (22.9% vs. 
12.5%, p=0.111). Together, these data suggest that CBD cases had spent a greater 
percentage of their work time directly exposed to beryllium than controls or BeS cases, 




Reconstructed beryllium exposures comparing cases and controls are shown in 
Table III-IV. CBD cases had significantly higher cumulative exposures (median=1.46 
µg/m3-years) and lifetime weighted average exposures (median=0.072 µg/m3) than either 
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BeS cases (median=0.11 µg/m3-years, p=0.001 and 0.009 µg/m3, p=0.001) or controls 
(median=0.39 µg/m3-years, p=0.018 and 0.03 µg/m3, p =0.008). Conversely, BeS cases 
had lower cumulative exposures (median=0.11 µg/m3-years) than controls (median=0.39 
µg/m3-years, p=0.034) and a trend toward lower lifetime weighted average exposure 
(median=0.01 µg/m3 vs. 0.03 µg/m3, p=0.064). There were no significant differences in 
any exposure characteristics between confirmed BeS cases and those classified as 
unconfirmed BeS (data not shown). Separating the lifetime weighted exposures into 
quartiles (≤ 0.001 µg/m3, > 0.001 to ≤ 0.03 µg/m3, > 0.03 to ≤ 0.17 µg/m3, and > 0.17 
µg/m3) demonstrated that CBD cases had a higher percentage of subjects with exposures 
over 0.17 µg/m3 (41.0%) compared to controls (22.3%, p=0.016). In addition, a greater 
frequency of CBD cases (32.8%) tended to work in the highest tasks based exposures 
compared to controls (20.0%, p=0.120). Interestingly, BeS cases were more likely to 
have maximum task based exposures less than 0.02 µg/m3 (35.7% compared to 19.2% of 
controls, p=0.017, and 13.1% of CBD cases, p=0.013).  
 
Genotype characteristics 
As shown in Table III-Vb, both BeS cases (92.9%, p < 0.001) and CBD cases 
(83.6%, p < 0.001) were more likely to carry an E69 compared to controls (38.0%). Cases 
were also more likely to carry two copies of E69 compared to controls (25.7% of BeS 
cases and 19.7% of CBD cases vs. 4.3% of controls with p < 0.001 and p=0.02 
respectively). After correcting for multiple comparisons, the only significant allele 
specific differences noted in Table III-Va were that BeS cases were more likely to be 
carriers of the *0201 and *0601 alleles and CBD cases were more likely to be carriers of 
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the *0601 allele compared to controls. When combined (Table III-Vb), the rarer non-*02 
E69 alleles were present at greater frequency in both BeS cases (55.7%, vs. 14.1% of 
controls, p < 0.001) and CBD cases (60.7% vs. controls, p < 0.001). The differences were 
not nearly as significant when BeS cases with the more common *02 genotype were 
compared to controls (BeS 52.9% vs. 26.7% of controls, p=0.005). Interestingly, the 
frequency of the *02 genotype in CBD cases (39.3%) did not differ significantly from 
controls.  No significant differences were noted in any genotype frequency between BeS 
and CBD cases or between confirmed and unconfirmed cases of BeS. 
 
Multivariate analyses 
Increasing lifetime weighted exposure and E69 were associated with increased 
odds of CBD in our logistic regression models. In contrast, while E69 was highly 
predictive of BeS odds in logistic regression models, beryllium exposure metrics 
including those representing cumulative, average, and short-term high exposure were not 
associated with BeS odds. Demographic variables including race, ethnicity, gender, age, 
and year of hire were not significant predictors or confounders in the odds of BeS or 
CBD. 
The significant multivariate predictors of BeS derived from logistic regression are 
presented in Table III-VI. The model showed point estimates of increasing odds of BeS 
with carriage of a single *02 allele (OR: 12.01, 95% CI: 4.28-33.71), carriage of a single 
rarer non-*02 allele (OR: 29.54, 95% CI: 10.33-84.53), and E69 copy number with one 
*02 allele plus one non-*02 E69 allele (OR: 55.68, 95% CI: 14.8-209.40). In addition, 
increased odds of BeS was associated with having worked fewer than five years at the 
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facility (OR: 2.83, 95% CI: 1.31-6.13). If a more simplistic model is used, adjusting for 
time spent working at the facility, the carriage of any E69 allele increases the odds of 
BeS 22-fold (OR: 21.89, 95% CI: 8.43-56.80)  (data not shown). Beryllium exposure 
covariates including lifetime weighted average exposure, cumulative exposure, and or 
short term maximum task-based exposure were not significant predictors of BeS. Race, 
ethnicity, gender, smoking status, and first-order interactions also did not contribute 
significantly nor confound the relationship between BeS and other variables in the model. 
Using a similar logistic regression model, multivariate predictors of CBD are 
shown in Table III-VIIa and Figure 3-1.  Of note, carriage of a single *02 allele (OR: 
3.46, 95% CI: 1.42-8.43), carriage of a single rarer non-*02 E69 allele (OR: 11.97, 95% 
CI: 5.12-28.00), and E69 copy number with one *02 allele plus one non-*02 E69 allele 
(OR: 22.54 95% CI: 7.00-72.62) were associated with increased odds of CBD. In 
addition, each unit increase in lifetime weighted average beryllium exposure (OR: 2.22, 
95% CI: 1.21-4.07) was associated with increased odds of CBD. In a simplified model, 
carriage of any E69 was associated with a nearly eight-fold increased CBD odds (OR: 
7.61, 95% CI: 3.66-15.84) when adjusting for lifetime weighted average exposure (OR: 
2.27, 95% CI: 1.26-4.09, data not shown in tables). In an alternate model, cumulative 
beryllium exposure was also a significant predictor of CBD showing a small (< 10%) 
increase in CBD odds per unit increase in cumulative exposure (OR: 1.04, 95% CI: 1.00-
1.07, data not shown). As lifetime weighted average and cumulative exposure were 
highly correlated (r=0.91), only a single exposure risk factor could be included in the 
model. In the lifetime weighted average exposure model, neither excluding an exposure 
outlier (10.7 µg/m3) nor excluding all those exposed above a lifetime weighted average of 
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2 µg/m3 impacted the genetic regression coefficients or odds ratios significantly, although 
the latter did impact the lifetime weighted average estimate, more than doubling the 
regression coefficient. As with BeS, race, ethnicity, gender, smoking status, and first-
order interactions were not significant predictors of CBD nor confounders of other 
variables and CBD odds.   
CBD odds ratio estimates were determined by genetic factor and exposure level to 
estimate how these varied with increasing exposure. The additive relationship between 
exposure and genetics is illustrated in Table III-VIIb and Figure 3-1. Figure 3-1 
demonstrates the output of the logistic regression model from Table III-VIIa and 
illustrates that the baseline probability of CBD varies by specific E69 allele or E69 copy 
number and increases with increasing exposure. Considering the current OSHA 
Permissible Exposure Level (2.0 µg/m3), point estimates of CBD odds range from five-
fold increase for E69 negative genotypes to a more than 100-fold increase for E69 
homozygotes. Table III-VIIb also illustrates that compliance with a reduced exposure 
level, such as 0.1 µg/m3, could potentially reduce the odds of CBD nearly five-fold across 
all levels of E69 status.  
 
Discussion 
In the largest case-control study of beryllium exposed workers to date, we 
evaluated the relationship between quantitative beryllium exposure estimates in 
combination with HLA DPB1 E69 genotype in risk of BeS and CBD. We noted increased 
exposure associated with CBD as compared to controls which was evident whether 
considering self-reported exposure assessments or quantitative exposure reconstructions. 
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However, no exposure-response relationship was apparent for BeS, even with inclusion 
of genetic risk factors. For both CBD and BeS, E69 conferred increased odds in the 
absence and presence of exposure variables as has been shown previously in the study in 
Chapter 2 of this dissertation as well as other studies.(26-32, 34) We found that odds of BeS 
and CBD appear to be greater among carriers of the rarer non-*02 HLA-DPB1 E69 
alleles, and among HLA-DPB1 E69 homozygotes even after adjusting for beryllium 
exposure. Most importantly, we found evidence supporting an additive relationship 
between exposure and genetic susceptibility via E69 in the odds of CBD and provided 
evidence suggesting an exposure-response for CBD and lack thereof for BeS after 
adjusting for E69 genetic risk factors.  
The finding of an exposure-response relationship for CBD and the additive 
relationship between exposure and genetics has implications for standard setting in the 
workplace, at a time when OSHA is reconsidering revising the currently out-of-date 
beryllium exposure standard. In this study, odds of CBD were associated with higher 
lifetime weighted average and cumulative exposures, whereas increasing exposure was 
not a risk factor for BeS. This confirms the previous work by Viet et al.(17) at the RFETS 
facility showing significant relationships for both cumulative and mean exposures and 
CBD, but not BeS. Also, confirming previous reports (12, 57, 58), we identified CBD cases 
at very low apparent exposures with three CBD cases reporting no known beryllium 
exposure and an additional five reporting never having worked in areas or tasks where 
reconstructed exposures exceeded 0.02 µg/m3. Thus, this study, while clearly showing 
higher prevalence of CBD at higher exposure levels, fails to demonstrate a threshold for 
the development of CBD. In contrast, for BeS, there was no evidence of either an 
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exposure threshold or an exposure-response relationship as evidenced by the tendency for 
BeS cases to be overrepresented in the lowest lifetime weighted average exposure 
quartile and with over a third of BeS cases never having worked in areas or processes 
where reconstructed exposures exceeded 0.02 µg/m3. This frequent occurrence of BeS 
among workers with only minimal known exposure combined with evidence of an 
exposure-response relationship for CBD has important implications for worker protection 
both in terms of medical surveillance and removal from exposure. The findings suggest 
even minimally exposed workers should be screened using the BeLPT to detect BeS and 
facilitate early removal from exposure and possible prevention of progression to CBD.  
This study also confirms the individual contributions of exposure and genetics 
(E69 status) to the development of CBD. In our current study, carriage of any E69 
conferred about an eight-fold increased odds of CBD and each unit increase in lifetime 
weighted average beryllium exposure increased CBD odds approximately two-fold. This 
eight-fold increased odds for carriage of any HLA-DPB1 E69 variant is similar to the 
seven-fold increased odds identified in our previous study at another nuclear weapons 
plant in Chapter 2 of this dissertation and is within the confidence limits of the 12-fold 
increased odds from the initial gene-environment study of workers in the primary 
beryllium industry(27). In comparing the risks from genetics and exposure, our current 
findings suggest that, in terms of CBD odds, carriage of any single E69 allele even in 
extremely low exposures incurs similar odds as exposure to an average beryllium 
concentration of 4 µg/m3 for those without an E69 allele. This eight-fold increased odds 
for any E69 appears to be differentially distributed when considering E69 genotype, with 
carriers of only a single copy of the more common *02 alleles only at a three-fold 
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increased odds, those with the rarer non-*02 genotypes at a nearly 12-fold increased 
odds, and those with two E69 allele copies at more than 20-fold increased odds. Among 
those exposed at an average of 0.2 µg/m3, which is 10% of the current OSHA Permissible 
Exposure Level and the current Department of Energy action level, our model suggests 
those without an E69 allele would be at an approximately 20% increased odds of CBD, 
those with a single *02 allele would be at a four-fold increased odds of CBD, those with a 
rarer non-*02 allele would be at a 14-fold increased odds of CBD, and E69 homozygotes 
would be at a more than 25-fold increased odds of CBD. This additive relationship 
between HLA-DPB1 E69 status and exposure is also similar to that identified in our 
previous study in Chapter 2 of this dissertation. 
In terms of policy development, exposure reduction has the potential to provide a 
greater public health benefit than pre-employment genetic testing. As has been presented 
before(59, 60), the low prevalence of BeS and CBD among those exposed and the high 
carrier frequency of E69 combine to produce an unacceptable positive predictive value 
for using the E69 marker to determine eligibility for employment in the beryllium 
industry. Results from this study continue to support this assertion. From this study, 
considering the greatest genetic risk factors, non-*02 E69 genotype or E69 
homozygosity, for the odds of CBD with an odds ratio of approximately 12 for rare 
genotype and 22 for homozygosity, and assuming a generous CBD prevalence rate of 
5%, a non-*02 genotype frequency of 15%, and a 4% frequency of E69 homozygotes, the 
positive predictive value of genetic testing is only 23% for non-*02 genotype and only 
59% for E69 homozygotes. This low positive predictive value implies that for every 100 
individuals denied employment due to this genetic trait, the majority of them would not 
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have developed CBD which represents unacceptable workplace discrimination. Exposure 
reduction, on the other hand, reduces the odds for all exposed, regardless of E69 status, 
and might reduce the progression from BeS to CBD. Based on our models, a reduction in 
exposure from the current OSHA limit of 2 µg/m3 to a new limit of 0.1 µg/m3 would 
result in a nearly five-fold reduction in the odds of CBD for all genetic types.  
The models from our case-control study can be extrapolated to project the 
probability of CBD for workers at RFETS given the facility prevalence of CBD of 1.7% 
identified in a stratified sample by Kreiss et al.(12), and assuming the population 
characteristics of the participants in this study are representative of all workers at the site. 
The proportion of participants with CBD in our model is 19% which is approximately a 
factor of 10 higher than the facility prevalence. The probability of CBD predicted by our 
model at a lifetime weighted average exposure of 0.2 µg/m3 is 6% for those with E69 
negative genotypes, 18% for those with a single *02 allele, 44% for those with a single 
rarer non-*02 E69 allele, and 58% for E69 homozygotes. Assuming the genotype 
frequencies of the workers at the entire site are similar to the controls in this study (see 
Table III-Vb, 62% for E69 negative, 22% for *02 genotypes, 11% for non-*02 E69 
genotypes, and 4% for homozygotes), a weighted average probability of CBD can be 
calculated ([0.62 x 0.06] + [0.22 x 0.18] + [0.11 x 0.44] + [0.04 x 0.58] = 0.15) 
suggesting across the study population the probability of CBD at 0.2 µg/m3 is 15%. This 
probability can be extrapolated using the factor of 10 to account for the difference in the 
proportion of CBD cases between the case-control study and the facility as a whole 
indicating the odds of CBD resulting from a 0.2 µg/m3 lifetime weighted exposure is 
1.5%. From an occupational exposure limit point of view, this suggests strict compliance 
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with an exposure limit of approximately 0.8 µg/m3 (assuming a lognormal distribution 
and a geometric standard deviation of three) using an upper tolerance limit approach as 
described by Mulhausen et al.(55) would result in a CBD prevalence of about 1.5% in an 
exposed population. This estimate is much higher than the 1 in 200 (0.5%) odds of CBD 
at an occupational exposure limit of 2 µg/m3 suggested by Viet et al.(17). Using the same 
extrapolation process, a lifetime weighted average exposure of 0.02 µg/m3 and associated 
0.08 µg/m3 occupational exposure limit would reduce the CBD prevalence in an exposed 
population to approximately 1.3% due to the relatively flat exposure response at the 
lower end.  
Our multivariate model for BeS suggested increased odds for those working fewer 
than five years at RFETS. This apparent reduced odds was consistent with that identified 
in our previous study in Chapter 2 of this dissertation showing decreasing odds of CBD 
and BeS combined with increasing work years. While there have been  reports of BeS 
occurring within a short period of time after first exposure (22, 61, 62) and others have 
reported similar protective effects in multivariate models (63), this study would likely not 
detect early BeS as most of the cases were first screened many years after first exposure 
to beryllium. Only 20% of BeS cases in this study were diagnosed as current workers. 
These cases were diagnosed on average 17 years after starting work at the facility with all 
diagnosed more than six years after starting work at the facility. It is more likely this 
increased odds for short-term workers is an artifact of study design as our study did not 
include frequency matching for the number of years worked. It is also possible that this 
effect was a result of the increased participation by long term workers in the control 
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group. However, this finding suggests that workers exposed for only a short time are at 
risk of BeS. 
 
Limitations 
Exposure misclassification could have impacted our results. However, one of the 
strengths of the study is its detailed exposure reconstruction in which the use of 
individual interviews accounts for the large variation of work composition within a single 
job classification. This attention to exposure at the individual level was likely one of the 
reasons that this study was able to identify an exposure-response relationship for CBD 
where others using grouping strategies at the job classification level have failed. In this 
study, cumulative exposures may have been overestimated for cases as exposures accrued 
until the date of BeS or CBD diagnosis which was likely much later than the date of 
disease development. The use of reported time percentages to calculate average and 
cumulative exposures likely resulted in lower exposure estimates than would have been 
assigned using methods relying on grouping strategies at the job classification level. The 
use of industrial hygiene data from other time periods and facilities in the development of 
the task exposures likely resulted in misclassification on an absolute µg/m3 scale, but less 
misclassification on a relative scale for comparing study participants. In assigning 
exposure estimates to tasks rather than individuals, the misclassification on both the 
absolute and relative scale should have been non-differential. In spite of these potential 
misclassifications, we did find exposure response relationships for CBD in our 
multivariate models.  
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Conclusions 
This is the largest study to evaluate E69, a well known marker of susceptibility 
for BeS/CBD, along with exposure in the risk of beryllium related health effects. In this 
study, E69 carriage and beryllium exposure each contributed individually to the odds of 
CBD. In contrast, E69 genetic risk factors were highly significant in the prediction of 
BeS, but reconstructed exposures and exposure surrogates did not contribute to BeS risk. 
Our results also suggest that increased odds for both CBD and BeS conferred by carriage 
of E69 alleles appear to be differentially distributed by genotype with carriers of rarer 
non-*02 E69 alleles and E69 homozygotes at higher odds than those with the more 
common *02 genotypes. The study demonstrates higher prevalence of CBD at higher 
exposure levels suggesting an exposure-response relationship, but fails to define a 
threshold below which disease is not apparent. Future studies will be needed to address 
interactions with other genes in the HLA region and the effects of exposure on CBD 
severity as higher exposures may be more important with increasing CBD related 
impairment. Regardless, this study supports efforts at exposure reduction in the 
workplace aimed at the most susceptible population, those with the E69 genetic variant.  
It also supports increased medical surveillance for early detection of BeS and removal 
from exposure to reduce the risk of progression from BeS to CBD. 
 
 





























Assembly/Inspection        
 General assembly work with Be parts ‘52-‘05 0.13     7 
 Hand polishing or etching Be parts ’52-‘85 1.0 ‘86-‘05 0.14   7 
 Brazing/Welding Be parts  ’52-‘85 1.32 ‘86-‘05 0.7   1 
 Inspection or handling of Be parts ’52-‘85 0.71 ‘86-‘05 0.15   6 
 Work within 5 feet of Be inspection operationsd ’52-‘85 0.36 ‘86-‘05 0.075   6e 
 Work in same room as Be inspection operationsd ’52-‘85 0.07 ‘86-‘05 0.015   6e 
 Work in same building as Be inspection operationsd ’52-‘85 0.007 ‘86-‘05 0.0015   6e 
Machining        
 Cutting Be with a band saw ‘52-‘05 1.78     8 
 Machining Be parts (mill, lathe, bore) ’52-‘74 2.56 ‘75-‘85 1.19 ‘86-‘05 0.052 2 
 Hand grinding of Be parts ‘52-‘05 0.56     1 
 Machine grinding Be parts ’52-‘74 3.16 ‘75-‘05 0.56   7 
 Machining BeCu parts ‘52-‘05 0.09     8 
 Work within 5 feet of a Be machining operationd  ’52-‘74 1.28 ‘75-‘85 0.6 ‘86-‘05 0.026 2e 
 Work in same room as a Be machining operationd ’52-‘74 0.35 ‘75-‘85 0.16 ‘86-‘05 0.007 4 
 Work in same building as a Be machining operationd  ’52-‘74 0.035 ‘75-‘85 0.016 ‘86-‘05 0.0007 4e 
Foundry        
 Be casting and mold breakout (old foundry,444) ’52-‘85 73.0 ‘86-‘05 2.0   1, 6 
 Be casting and mold breakout (new foundry, 865) ‘52-‘05 2.0     6 
 Work within 5 feet of Be casting (old foundry, 444)d ’52-‘85 36.0 ‘86-‘05 1.0   1e, 6e 
 Work within 5 feet of Be casting (new foundry, 865)d ‘52-‘05 1     6e 
 Work in same room as Be casting (old foundry, 444)d ’52-‘85 7.3 ‘86-‘05 0.1   1e, 6e 
 Work in same room as Be casting (new foundry, 865)d ‘52-‘05 0.2     6e 
 
aSpecifies the time period of similar exposure for the task. Tasks did not necessarily occur in every year in the time period. 
bSpecifies the arithmetic mean of the exposure for the task and time period combination 
cData sources used to establish exposure estimates for each time period and task combination – see methods section for numbers. 
dFor these tasks, there was only indirect exposure to beryllium. 


































Forming         
 Hot pressing of Be parts ’52-‘05 1.03     1 
 Rolling Be parts (sheet rolling) ’52-‘05 0.18     1 
 Cutting Be using a shear ’52-‘05 1.28     1 
 Annealing/Heat treating Be parts ’52-‘05 0.2     1, 8 
 Work within 5 feet of Be rolling/pressingd ’52-‘05 0.3     1e 
 Work in same room as Be rolling/pressingd  ’52-‘05 0.06     1e 
 Work in same building as a Be rolling/pressingd ’52-‘05 0.006     1e 
Laboratory         
 Metallurgical testing of Be parts ’52-‘05 0.16     5 
 Laboratory analysis of Be samples ’52-‘85 0.26 ’86-‘05 0.13   6 
 Work within 5 feet of Be laboratory operationd ’52-‘05 0.08     5e 
 Work in same room as a Be laboratory operationd ’52-‘05 0.016     5e 
 Work in same building as Be laboratory operationd ’52-‘05 0.002     5e 
Treating/Finishing         
 Plating/Chemical milling/Etching beryllium parts ’52-‘05 0.32     7 
 Operating metal spray/plasma machine with Be ’52-‘05 0.52     5 
 Grit blasting or sand blasting Be parts ’52-‘05 0.3     1 
 Work within 5 feet of Be plating/chem... Millingd ’52-‘05 0.16     7e 
 Work in same room as a Be plating/chem... Millingd ’52-‘05 0.03     7e 
 Work in same building as a Be plating/chem.. Millingd ’52-‘05 0.003     7e 
 
aSpecifies the time period of similar exposure for the task. Tasks did not necessarily occur in every year in the time period. 
bSpecifies the arithmetic mean of the exposure for the task and time period combination 
cData sources used to establish exposure estimates for each time period and task combination – see methods section for numbers. 
dFor these tasks, there was only indirect exposure to beryllium. 




































Maintenance and D&D         
 Cleaning Be contaminated machines/surfaces ’52-‘85 4.5 ‘86-‘94 2.25 ‘95-‘05 0.05 1 
 Maintenance on Be contaminated machines/equipment ’52-‘85 1.0 ‘86-‘94 0.18 ‘95-‘05 0.04 7, 6, 3 
 Filter replacement/testing on Be contaminated systems ‘52-‘05 23.9     1 
 Work in same building as a Maint/D&D operationd ’52-‘85 0.045 ‘86-‘94 0.023 ‘95-‘05 0.0005 3e 
Waste         
 Washing Be contaminated laundry ‘52-‘05 0.3     1 
 Collecting Be waste materials (chip collecting) ’52-‘85 23.9 ’86-‘05 3.3   1, 8 
 Crushing Be parts/shapes ’52-‘85 36.4 ’86-‘05 3.3   1 
 Be waste packaging/re-packaging ’52-‘85 0.6 ’86-‘05 0.31   3 
Miscellaneous         
 Oversight within 5 feet of unspecified Be activitiesd ’52-‘74 0.93 ‘75-‘85 0.42 ‘86-‘05 0.06 Wt Avgf 
 Oversight in same room as unspecified Be activitiesd ’52-‘74 0.18 ‘75-‘85 0.075 ’86-‘05 0.015 Wt Avgf 
 Oversight in same bldg as unspecified Be activitiesd ’52-‘74 0.026 ‘75-‘85 0.012 ‘86-‘05 0.001 Wt Avgf 
 
aSpecifies the time period of similar exposure for the task. Tasks did not necessarily occur in every year in the time period. 
bSpecifies the arithmetic mean of the exposure for the task and time period combination 
cData sources used to establish exposure estimates for each time period and task combination – see methods section for numbers. 
dFor these tasks, there was only indirect exposure to beryllium. 
eSpecifies source of base data from numbering in methods section, actual exposure estimates were extrapolated based on the method outlined in the 
methods section. 



















Median age (range)a 67 (41 – 89) 67 (41 – 89) 65 (45 – 84) 65 (49 – 86)  
Gender, n (%)b      
 Male 341 (88.3%) 230 (90.2%) 55 (78.6%) 56 (91.8%)  
 Female 45 (11.7%) 25 (9.8%)c 15 (21.4%)c,e 5 (8.2%)e 0.013c, 0.050e 
Race, n (%)b      
 Caucasian 377 (97.7%) 252 (98.8%) 68 (97.1%) 57 (93.4%)  
 African American 9 (2.3%) 3 (1.2%)d 2 (2.9%) 4 (6.6%)d 0.028d 
Ethnicity, n (%)b      
 Hispanic 24 (6.2%) 11 (4.3%)c 8 (11.4%)c 5 (8.2%) 0.039c 
 Non-Hispanic 362 (93.8%) 244 (95.7%) 62 (88.6%) 56 (91.8%)  
Smoking status, n (%)b      
 Current 23 (6.0%) 13 (5.1%)c 8 (11.4%)c,e 2 (3.3%)e 0.094c, 0.104e 
 Former 203 (52.6%) 135 (52.9%) 34 (48.6%) 34 (55.7%)  
 Never 160 (41.4%) 107 (42.0%) 28 (40.0%) 25 (41.0%)  
Median year of hire (range)a 1969 (1952 - 1998) 1968 (1952 – 1993) 1972 (1952 – 1998) 1969 (1952 – 1990)  
Median years at facility (range)a 15.0 (0.2 – 40.7)  15.8 (0.2 – 40.7)c 12.6 (0.5 – 33.7)c 16.8 (1.0 – 40.0) 0.020c 
 aCompared using Kruskal-Wallis test followed by pairwise Mann-Whitney tests when significant 
bCompared using χ2 or Fisher’s exact method 
cComparison between BeS and Controls. 
dComparison between CBD and Controls. 
















Any reported exposure to Be, n (%)a 333 (86.3%) 223 (87.4%)c 54 (77.1%)c,e 56 (91.8%)e 0.111c, 0.093e 
Median year of 1st Be exposure, (range)b 1970 (1952-1996) 1969 (1952-1971) 1976 (1952-1996) 1969 (1953-1990)  
Highest reported Be exposure, n (%)a      
 Any direct Be exposure 233 (60.4%) 159 (62.3%)c 32 (45.7%)c,e 42 (68.9%)e 0.039c, 0.026e 
 a. Directly alter Be part 112 (29.0%) 72 (28.2%) 15 (21.4%)e 25 (41.0%)e 0.066e 
 b. Contact with Be waste materials 90 (23.3%) 63 (24.7%) 13 (18.6%) 14 (23.0%)  
 c. Contact with finished Be part 31 (8.0%) 24 (9.4%) 4 (5.7%) 3 (4.9%)  
 Any indirect Be exposure 100 (25.9%) 64 (25.1%) 22 (31.4%) 14 (22.9%)  
 d. Work within 5 ft. of Be operation 25 (6.5%) 18 (7.1%) 2 (2.9%) 5 (8.2%)  
 e. Work in same room as Be operation 17 (4.4%) 12 (4.7%) 4 (5.7%) 1 (1.6%)  
 f. Work in same bldg as Be operation 58 (15.0%) 34 (13.3%)c 16 (22.9%)c 8 (13.1%) 0.183c 
 No known exposure to Be 53 (13.7%) 32 (12.5%)c 16 (22.9%)c,e 5 (8.2%)e 0.111c, 0.093e 
Median percent of work time exposed to Be (range)b      
 Directly (categories a – c above) 1.3% (0-100%) 1.4%(0-95.0%)c,d 0% (0-100%)c,e 4.3% (0-100%)d,e 0.061d, 0.097c, 0.009e 
 Indirectly (categories d – f above) 5.2% (0-100%) 6.1% (0-100%) 3.1% (0-100%) 10.0% (0-100%)  
 Directly or indirectly 16.9% (0-100%) 15.9% (0-100%) 10.6% (0-100%) 33.6% (0-100%)  
Ever exposed to Be oxide, n (%)a 22 (5.7%) 13 (5.1%) 5 (7.1%) 4 (6.6%)  
Ever worked as a Be machinist, n (%)a 48 (12.4%) 33 (12.9%) 6 (8.6%) 9 (14.7%)  
 aCompared using χ2 or Fisher’s exact method, p-values Bonferroni corrected (n=3) 
bCompared using Kruskal-Wallis test followed by pairwise Mann-Whitney tests when significant 
cComparison between BeS and Controls 
dComparison between CBD and Controls 

















Median cumulative Be exposure  
in µg/m3-years (Mean)b 0.35 (3.68) 0.39 (2.43)
c,d 0.11 (2.96)c,e 1.46 (9.71)d,e 0.034c, 0.018d, 0.001e 
Median lifetime weighted average Be exposure 
 in µg/m3 (Mean)b 0.03 (0.24) 0.03 (0.15)
c,d 0.01 (0.25)c,e 0.07 (0.64)d,e 0.064c, 0.008d, 0.001e 
Lifetime weighted average exposure quartiles, n (%)a      
 ≤ 0.001 µg/m3 91 (23.6%) 57 (22.3%)c 24 (34.3%)c,e 10 (16.4%)e 0.132c, 0.081e 
 > 0.001 to ≤ 0.03 µg/m3 109 (28.2%) 74 (29.0%) 21 (30.0%) 14 (22.9%)  
 > 0.03 to ≤  0.17 µg/m3 89 (23.1%) 67 (26.3%)c 10 (14.3%)c 12 (19.7%) 0.117c 
 > 0.17 µg/m3 97 (25.1%) 57 (22.3%)d 15 (24.4%)e 25 (41.0%)d,e 0.016d, 0.066e  
Maximum task-based exposure, n (%)a      
 < 0.02 µg/m3 82 (21.2%) 49 (19.2%)c 25 (35.7%)c,e 8 (13.1%)e 0.017c, 0.013e 
 ≥ 0.02 and < 0.05 µg/m3 30 (7.8%) 17 (6.7%) 7 (10.0%) 6 (9.8%)  
 ≥ 0.05 and < 0.10 µg/m3 7 (1.8%) 5 (2.0%) 2 (2.86%) 0 (0%)  
 ≥ 0.10 and < 0.20 µg/m3 27 (7.0%) 18 (7.1%) 6 (8.6%) 3 (4.9%)  
 ≥ 0.20 and < 0.50 µg/m3 24 (6.2%) 16 (6.3%) 4 (5.7%) 4 (6.6%)  
 ≥ 0.50 and < 1.0 µg/m3 29 (7.5%) 24 (9.4%) 2 (2.9%) 3 (4.9%)  
 ≥ 1.0 and < 2.0 µg/m3 100 (25.9%) 75 (29.4%)c 8 (11.4%)c.e 17 (27.9%)e 0.005c, 0.075e 
 ≥ 2.0 µg/m3 87 (22.5%) 51 (20.0%)d 16 (22.9%) 20 (32.8%)d 0.120d 
 aCompared using χ2 or Fisher’s exact method, p-values Bonferroni corrected (n=3) 
bCompared using Kruskal-Wallis test followed by pairwise Mann-Whitney tests when significant 
cComparison between BeS and Controls 
dComparison between CBD and Controls 






Table III-Va – Comparison of HLA-DPB1 genotype frequency among CBD, BeS, and controls 







E69 Genotypes     
a. *0201 67 (26.3%)b 36 (51.4%)b 21 (34.4%) 0.011b 
b. *0202 1 (0.4%) 2 (2.9%) 3 (4.9%)  
c. *0601 3 (1.2%)b,c 9 (12.9%)b 11 (18.0%)c 0.007b, < 0.001c
d. *0801 0 (0) 1 (1.4%) 0 (0)  
e. *0901 2 (0.8%) 4 (5.7%) 4 (6.6%)  
f. *1001 11 (4.3%) 9 (14.8%) 9 (12.9%)  
g. *1301 14 (5.5%) 5 (8.2%) 7 (10.0%)  
h. *1601 1 (0.4%) 2 (3.3%) 2 (2.9%)  
i. *1701 4 (1.6%)b,c 7 (11.5%)b 7 (10.0%)c 0.226b, 0.113c 
j. *1901 1 (0.4%) 0 (0%) 0 (0%)  
Non-E69 Genotypes     
k. *0101 20 (7.8%) 7 (10.0%) 5 (8.2%)  
l. *0301 37 (14.5%) 6 (8.6%) 6 (9.8%)  
m. *0401 187 (73.3%)b,c 35 (50.0%)b 26 (42.6%)c 0.037b, 0.001c 
n. *0402 62 (24.3%)b 2 (2.9%)b 9 (14.8%) 0.001b 
o. *0501 6 (2.3%) 1 (1.4%) 3 (4.9%)  
p. *1101 8 (3.1%) 1 (1.4%) 2 (3.3%)  
q. *1401 10 (3.9%) 2 (2.9%) 1 (1.6%)  
r. *1501 1 (0.4%) 1 (1.4%) 0 (0%)  
s. *2001 3 (1.2%) 0 (0%) 0 (0%)  
t. *2301 2 (0.8%) 0 (0%) 0 (0%)  
 aCompared using χ2 or Fisher’s exact method, p-values Bonferroni corrected (n=87) 
bComparison of BeS cases to controls 








Table III-Vb – Comparison of grouped HLA-DPB1 E69 genotype frequency among CBD, BeS, and controls 







Grouped E69 Genotypes     
 Any E69 allele 97 (38.0%)b,c 65 (92.9%)b 51 (83.6%)c < 0.001b,c 
 Any *02 68 (26.7%)b 37 (52.9%)b 24 (39.3%) 0.007b 
 Single *02 with non-E69 57 (22.3%) 21 (30.0%) 13 (21.3%)  
 Any Non-*02 36 (14.1%)b,c 39 (55.7%)b 37 (60.7%)c < 0.001b,c 
 Single E69+ Non*02 with non-E69 29 (11.4%)b,c 26 (37.1%)b 26 (42.6%)c < 0.001b, < 0.001c 
 Any Two E69+ copies 11 (4.3%)b,c 18 (25.7%)b 12 (19.7%)c < 0.001b, 0.020c 
 Two E69+ copies (*02 alleles) 4 (1.6%) 5 (7.1%) 1 (1.6%)  
 Two E69+ copies (*02 + non-*02) 7 (2.75%)b,c 11 (15.7%)b 10 (16.4%)c 0.017b, 0.020c 
 Two E69+ copies (Non-*02 alleles) 0 (0%) 2 (2.9%) 1 (1.6%)  
 aCompared using χ2 or Fisher’s exact method, p-values Bonferroni corrected (n=87) 
bComparison of BeS cases to controls 












Table III-VI – Multivariate logistic regression model for BeS considering HLA-DPB1 E69 genotype 
Independent Variables Regression Coefficient 
Standard 
Error P value OR (95% CI) 
Intercept -3.72 0.48 < 0.001  
HLA-DPB1 E69 genotype     
 HLA-DPB1 E69-  Ref    
 Single HLA-DPB1*02 allele (with E69- allele) 2.48 0.53 < 0.001 12.01 (4.28-33.71) 
 Single HLA-DPB1 E69+ non *02 allele (with E69- allele) 3.39 0.54 < 0.001 29.54 (10.33-84.53) 
 E69 homozygote (*02 + non-*02 E69+) 4.01 0.68 < 0.001 55.68 (14.80-209.40) 







Table III-VIIa– Multivariate logistic regression model for CBD considering HLA-DPB1 E69 genotype and exposure 
Independent Variables Regression Coefficient 
Standard 
Error P value OR (95% CI) 
Intercept -2.92 0.34 < 0.001  
HLA-DPB1 E69- genotype     
 HLA-DPB1 E69-  Ref    
 Single HLA-DPB1*02 allele (with E69- allele) 1.24 0.45 0.006 3.46 (1.42-8.43) 
 Single HLA-DPB1 E69+ non *02 allele (with E69- allele) 2.48 0.43 < 0.001 11.97 (5.12-28.00) 
 E69 homozygote (*02 + non-*02 E69+) 3.11 0.60 < 0.001 22.54 (7.00-72.62) 











(with E69- allele) 
Single E69+ non-*02 
(with E69- allele) 
E69 homozygote 
(*02 + non-*02 E69+) 
0.02 µg/m3 1.02 (1.00-1.03) 3.52 (1.45-8.57) 12.16 (5.20-28.45) 22.90 (7.11-73.83) 
0.05 µg/m3 1.04 (1.01-1.07) 3.61 (1.48-8.77) 12.45 (5.32-29.14) 23.46 (7.27-75.69) 
0.10 µg/m3 1.08 (1.02-1.15) 3.75 (1.54 -9.14) 12.96 (5.53-30.37) 24.41 (7.55-78.96) 
0.20 µg/m3 1.18 (1.04-1.32) 4.06 (1.66-9.95) 14.03 (5.95-33.07) 26.43 (8.11-86.11) 
0.50 µg/m3 1.49 (1.10-2.02) 5.16 (2.02-13.16) 17.82 (7.25-43.81) 33.56 (9.90-113.76) 
1.0 µg/m3 2.22 (1.21-4.07) 7.68 (2.63-22.43) 26.52 (9.38-75.02) 49.95 (13.07-190.88) 











Figure 3-1 – Predicted probability of CBD by E69 genotype and lifetime weighted 
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COMPARISON OF THREE METHODS OF RETROSPECTIVE EXPOSURE 
ASSESSMENT IN A CASE-CONTROL STUDY OF BERYLLIUM SENSITIZATION 
AND CHRONIC BERYLLIUM DISEASE 
 
Abstract 
This report provides a comparison of three different, but related, retrospective 
exposure assessment methods applied to the participants of a case-control study 
evaluating the risk of beryllium sensitization (BeS) and chronic beryllium disease (CBD) 
in the nuclear weapons industry. 
Workers (n=386) from a former U.S. nuclear weapons production facility, Rocky 
Flats Environmental Technology Site (RFETS, Arvada, CO), were enrolled in a case-
control study including 70 individuals with BeS and 61 with CBD. Beryllium exposures 
for each participant were assessed using three different methods: 1) a traditional job 
exposure matrix (JEM method) that assigned beryllium exposures at the job title level 
based on interviews with three workers in each job title and assessment of available 
industrial hygiene exposure measurements; 2) individual worker interviews evaluating 
the tasks each worker performed followed by “expert” assessment of task exposures by 
two industrial hygienists (IHs) based solely on professional judgment based on their 
experience in the beryllium industry (IH rating method), and; 3) individual worker 
interviews as described in #2 followed by extensive analyses of historical facility-specific 
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and industry-wide data to assign exposures to tasks (IH data method). Task and 
participant exposures produced using these three methods were compared in terms of 
specificity, sensitivity, correlation, and absolute agreement. In addition, odds ratios from 
logistic regression analyses on the odds of CBD by exposure level were compared. 
Linear regression of task exposures from the IH rating and IH data methods 
indicated that IHs’ expert assessment of the average beryllium concentrations for each 
task accounted for approximately 65% of the variability in the task exposures assigned 
after extensive analyses of historical IH measurements. Compared to the IH data method, 
the JEM method had high specificity (0.94) but low sensitivity (0.27) considering a 
binary exposed/unexposed outcome. Participant exposure assignments using all three of 
the methods were significant predictors of increased CBD odds with odds ratios ranging 
from 1.51 (95% CI: 1.03-2.22) for each unit increase in lifetime-weighted average 
(LTWA) exposure for the JEM method to 2.50 (95% CI: 1.47-4.26) for each unit increase 
in LTWA exposure for the IH data method.  
A method of task exposure assessment relying solely on the professional 
judgment of IHs performed similarly to a method involving extensive analyses of 
historical IH measurements in terms of rank order assessment of average task exposure. 
Use of any of the three exposure assessment methods resulted in the identification of 
increasing odds of CBD with increasing LTWA exposure. Exposure misclassification 
likely attenuated the odds ratio point estimates for the odds of CBD by approximately 5% 





Retrospective exposure assessment is one of the most problematic elements of 
occupational case-control studies requiring intensive effort and resources to establish 
relatively valid and reliable estimates of past exposure. As the focus of occupational case-
control studies is to identify and compare disease risk factors in the most efficient manner 
possible, rarely does the opportunity arise to formally compare the performance of 
exposure estimates obtained using different methods. This report provides a comparison 
of three different, but related, retrospective exposure assessment methods applied to the 
participants of a case-control study evaluating the risk of beryllium sensitization (BeS) 
and chronic beryllium disease (CBD) in the nuclear weapons industry. 
Beryllium is a low-density metal with unique properties that make it highly 
desirable for use in a number of industries including automotive, electronics, 
communications, medical, defense, and aerospace. Workers exposed to aerosols 
generated by the fabrication of beryllium-containing materials are at risk for developing 
BeS and CBD. BeS is a Type IV, delayed hypersensitivity reaction, which can be 
observed as T-cell proliferation in beryllium-stimulated peripheral blood using the 
beryllium lymphocyte proliferation test (BeLPT).(1-3) In some individuals, BeS progresses 
to CBD, a lung disease characterized by non-caseating granulomas and interstitial 
infiltrates often leading to fibrosis. 
The risk of BeS and CBD appears to vary by workplace and by exposure level. 
Prevalences of up to 15% for BeS and 8% for CBD have been reported in cross-sectional 
studies of beryllium-exposed workforces.(2, 4) While these studies have clearly 
documented that higher exposures are associated with higher prevalences of BeS and 
 130
CBD, there have been consistent difficulties in defining the nature of the exposure-
response relationship.(5-7) Due to this previously ill-defined exposure-response 
relationship, we have recently completed a case-control study (Chapter 3) at a nuclear 
weapons manufacturing facility to further evaluate the exposure-response relationship 
and the influence of specific genetic factors in BeS and CBD. 
As part of this case-control study, we evaluated subjects’ beryllium exposures 
using three different exposure assessment methods. The first method, termed the JEM 
method, involved using a previously created facility specific job exposure matrix (JEM) 
which assigned average beryllium exposures by year based on the job title and the 
specified work location (building) of the participant. From the average yearly exposures 
and the total time spent working at the facility, a lifetime weighted average (LTWA) 
exposure could be assigned to each subject. The second and third methods involved 
individual interviews with each subject to determine the tasks that they performed and the 
amount of time spent on each task. From these interviews, descriptions of subjects’ tasks 
were compiled into a list of beryllium exposure tasks. For the second exposure 
assessment method, termed the IH rating method, two industrial hygienists (IHs) each 
with over five years experience in beryllium industries were asked to estimate the 
average exposure in µg/m3 for each of the beryllium exposure tasks using only their 
professional knowledge of beryllium operations. For the third method, termed the IH data 
method, researchers compiled an extensive database of beryllium exposure measurements 
for each task from facility-specific historical data and other available industry-wide data. 
Using this database, researchers calculated time-period specific average exposures for 
each of the beryllium exposure tasks. Using the exposures assigned to each task by either 
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the IH rating method or the IH data method, LTWA beryllium exposures were assigned 
to each study participant using the amount of time the individual spent performing the 
task and the total time the individual spent working at the facility.  
There were several similarities and differences between the exposure assessment 
methods. All three methods used the same work history rosters as the foundation for 
establishing changes in job title and work assignment location over time. This work 
history roster remained unmodified in the JEM method and was modified based on 
subject interviews in the other two methods. In addition, the JEM and IH data methods 
relied on some of the same exposure data to establish task exposures. However, expanded 
beryllium exposure datasets, including those from other nuclear weapons facilities and 
those from private industry, were also used to determine task exposures for the IH data 
method. Key differences between the methods included: 1) the JEM method assigned the 
same average yearly exposure to all workers in a job classification while the IH rating 
and IH data methods assigned LTWA exposures independently to each individual 
subject; 2) the IH rating method used IH expert judgment to assign task-based exposures 
while both the JEM and IH data methods used actual IH exposure measurements; 3) the 
JEM and IH data methods accounted for differences in task-based exposure due to 
engineering control or work practice modifications over time at the facility by assigning 
multiple, time-specific exposures for each task while the IH rating method relied on a 
single index of exposure for each task; 4) the JEM method consisted of work histories 
and exposures covering the only the years 1952 to 1996 while the other two methods 
covered the entire work histories of all the participants up to 2006.  
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In spite of the differences in the exposure assessment methods, we hypothesized 
that use of any of the three methods would result in similar estimates of increased odds of 
CBD with increasing exposure. To address this hypothesis, we analyzed the data from a 
case-control study of a nuclear weapons production facility where beryllium components 
were fabricated using separate estimates of LTWA beryllium exposure calculated for 
each participant from each of the three exposure assessment methods.  The aims of the 
study were to: 1) compare task exposure estimates produced using the IH rating and IH 
data methods to assess the performance of IH “experts” in estimating beryllium 
exposures in the absence of exposure data; 2) compare subjects’ assigned LTWA 
exposures between all three methods in terms of sensitivity, specificity, and validity using 
the IH data method as a “gold” standard; 3) compare the CBD exposure-response profiles 
produced using LTWA exposures from each of the three methods to assess any important 




The current investigation was conducted among workers from Rocky Flats 
Environmental Technology Site (RFETS). This facility opened in 1951 for the express 
purpose of processing and machining plutonium, uranium, and other materials into a 
detonator or “trigger” for nuclear weapons. Starting in the late 1950s and continuing until 
approximately 1990, workers at this facility cast, pressed, rolled, machined, treated 
(plated, coated, etc.), and joined beryllium materials on a production scale at the facility. 
As a very large and diverse facility, including production, maintenance, and research 
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operations involving many different materials, not all RFETs employees were exposed to 
beryllium and those who were often worked only a small portion of their career with or 
around beryllium. In 1993, the site’s mission changed to cleanup and closure with the 
official decommissioning and closure of the facility in 2005. The best estimates indicated 
that approximately 15,063 production workers and 3,250 construction workers were 
employed at RFETS during the life of the plant.(8) At least 7,820 of these workers were 
part of a serial medical surveillance program which included testing with the BeLPT and 
resulted in at least 117 individuals diagnosed with CBD and 184 with BeS.(9)  
 
Case-control study recruitment and design 
While details on recruitment and study design for this case-control study are 
presented in Chapter 3, briefly, all workers ever working at RFETS and participating in 
beryllium medical surveillance were eligible to participate in the study. Participants were 
recruited through mailings and clinical contact at National Jewish Health. BeS cases by 
definition had two or more abnormal blood BeLPT results or an abnormal 
bronchoalveolar lavage (BAL) BeLPT. Some BeS cases had undergone a medical 
evaluation to rule-out CBD, others had not. CBD cases had evidence of BeS along with 
either: 1) pathological evidence of granulomatous inflammation on biopsy; or 2) both an 
abnormal BAL BeLPT and greater than 15% lymphocytes in BAL fluid. Controls were 
individuals who had worked at RFETS and had at least two normal blood BeLPTs and no 
abnormal blood BeLPTs. Controls were frequency matched approximately two to one to 
CBD and BeS cases based on gender, race, and decade of hire at RFETS. The study 
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protocol was reviewed and approved by the National Jewish Health Institutional Review 
Board. Written informed consent was obtained from each study participant.  
 
Exposure Assessment Methods 
Job exposure matrix (JEM) method 
A JEM was created at RFETS in the late 1990s to assess exposure to multiple 
chemicals including metals and solvents. Details on the creation of this JEM have been 
presented elsewhere(10), thus, only a brief description is provided here. The payroll 
department at RFETS recorded monthly job and building assignments for most of the 
workers on the site from 1952 and 1996. From these RFETS archived payroll records, the 
job title and work location (building) from one month each year was entered into a 
database for each of 13,480 workers at the plant. In order to assign chemical exposures to 
each of the year, job title, and building locations, historical records on chemical use and 
processes were reviewed for the 83 buildings at the facility. Twenty buildings were 
identified with potential exposure to chemicals with known acute or chronic health 
effects. For each of these 20 buildings, at least three workers from each job title within 
the building were interviewed to determine the potential exposures and task composition 
of their jobs. Workers were also asked about substantial process or work-practice changes 
that may have affected exposure in order to categorize tasks into time-periods of similar 
exposure. Using the task descriptions related to beryllium provided by the interviews, an 
IH reviewed the available beryllium exposure data from the facility for the specific time 
period of similar exposure to assign an average exposure in µg/m3 to the task. Further, 
using the task composition or percent time working in each task for the job title, the IH 
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constructed a yearly average beryllium exposure for the job title. The job title yearly 
averages were adjusted appropriately based on increases or decreases in production using 
the estimates of percent time provided in the interviews. Cumulative beryllium exposures 
were estimated by summing the yearly average beryllium exposures over workers’ 
employment histories. LTWA beryllium exposures were estimated by dividing the 
cumulative exposure by the total number of work years at the facility. In calculating 
cumulative and LTWA beryllium exposures, yearly average beryllium exposures were 
summed up to the year of employment termination or the last year of data availability 
(1996) for participants who continued to work at least through 1996. Beryllium exposures 
for BeS and CBD cases incurred after the date of diagnosis were not included in their 
cumulative exposure. For this case-control study, beryllium exposures were available in 
the JEM for 86% (332/386) of the participants. 
 
IH rating method 
Task exposure questionnaire 
A task exposure questionnaire was developed using information from focus 
groups of RFETS workers. This questionnaire was administered by one of four trained 
interviewers, with industrial hygiene or exposure assessment experience, using an 
interview script and work history from the JEM method to help refresh interviewees 
regarding the start and end dates of each work assignment. Participants were asked to 
verify the start and end dates for each job title assignment (i.e., machinist, chemical 
operator, electrician, etc.) along with an estimate of the average number of hours worked 
per week in the job. Participants were also asked to describe the specific tasks (i.e., lathe, 
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grind, plating, cleaning, etc.) performed for each job title assignment. For each task, 
participants were required to categorize their beryllium exposure into one of seven 
exposure categories listed in order of decreasing qualitative exposure: 1) directly altering 
a beryllium part; 2) contact with beryllium waste materials; 3) contact with finished and 
cleaned beryllium parts; 4) work within 5 feet of a beryllium operation with no direct 
beryllium contact; 5) work in the same room as a beryllium operation with no direct 
beryllium contact; 6) work in the same building as a beryllium operation with no direct 
beryllium contact; or 7) no known beryllium exposure. For each of the tasks, the 
participant provided a percentage of time spent performing the task and a percentage of 
time spent performing the task with beryllium.  
 
Task exposure assessment 
From the exposure questionnaires, a total of 50 unique combinations of exposure 
category and task were identified (Table IV-I) consisting of 27 combinations with direct 
beryllium exposure involving direct work with a beryllium part or with beryllium waste 
materials and 23 combinations with indirect beryllium exposure where there was no 
direct work with beryllium or beryllium waste materials, but instead proximity to a 
beryllium operation. Two IHs with each with over five years experience in the beryllium 
industry were provided with this list of 50 tasks. The IHs were asked to independently 
provide a single number representative of the arithmetic mean of the beryllium exposure 
on a µg/m3 scale that would have been expected for workers performing the task in the 
late-1970s and early-1980s. Following the independent assessments, the two IHs met to 
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describe their rationale in establishing each task exposure estimate and reach consensus 
on any discordant task exposure estimates. 
 
Participant exposure assessment 
The consensus task exposure estimates from the IHs were used to calculate a 
cumulative beryllium exposure by summing the job specific exposures obtained by 
multiplying the consensus task exposure estimates by the percent of time working with 
beryllium in that time period, the percent of time performing the tasks, the number of 
years spent in the job, and the ratio of the average number of work hours per week to 40 
hours. A LTWA exposure was calculated by dividing the cumulative exposure by the 
total number of work years. In calculating cumulative and LTWA exposures for each 
participant, beryllium exposure and work time were allowed to accrue over a work 
history for an individual until the date of employment termination for controls, or until 
the date of BeS or CBD diagnosis or employment termination for the cases, whichever 
came first.  
 
IH data method 
This method used the same exposure questionnaire data and combinations of 
exposure category and task described in the IH rating method (Table IV-I) and is 
described in detail in Chapter 3.  Briefly, the 50 combinations of exposure category and 
task were separated into one to three time periods of similar exposure based on installed 
controls and plant practices based on published information(11-13) and personal knowledge 
about beryllium production at RFETS. Each of the unique combinations of exposure type, 
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task, and time period constituted a cell of the task exposure matrix. Each cell involving 
direct exposure to beryllium was filled in using the arithmetic mean of the available 
exposure measurements from published (11-18) and study specific data closest in time 
period and task composition based on the judgment of the authors. As very little relevant 
data were available to fill in the cells involving indirect beryllium exposure and realizing 
that indirect exposures were closely related to direct exposures, we used a conservative 
method for assigning average exposures to these cells. Using the same established time 
periods, reported indirect exposures within 5 ft. of a beryllium task were assigned an 
average of 50% of the task, those in the same room 10% of the task, and those in the 
same building 1% of the task. Participant cumulative and LTWA exposures were 
determined using the same method outlined in the discussion on the IH rating method 
except that time-specific average task exposures were used rather than a single average 
exposure for each task. 
 
Statistical analysis 
We used SAS v. 9.1 (SAS Institute, Inc., Cary, NC) for statistical analyses. 
Univariate analyses of categorical variables were performed using chi-square and 
Fisher’s exact tests. Continuous unpaired variables were compared across the three 
groups (controls, BeS, and CBD) using the Kruskal-Wallis test followed by pair-wise 
comparisons using the Mann-Whitney test when significant. Differences in paired 
variables, including task exposures and participant exposures, were assessed using the 
non-parametric Wilcoxon-Rank Sum test. Since there was only a single exposure 
estimate for each task using the IH rating method and from one to three exposure 
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estimates for each task using the IH data method, comparisons of task exposures were 
performed between estimates corresponding to the late-1970s and early-1980s time 
period. Sensitivity, specificity, and Kappa scores were calculated comparing the exposure 
estimates from the IH data method to those from the IH rating method and the JEM 
method. For these calculations, the data were re-coded as a binary variable with zero 
exposure (0) defined as a LTWA exposure less than or equal to 0.02 µg/m3 and exposure 
(1) defined as a LTWA exposure greater than 0.02 µg/m3. Confidence intervals for 
sensitivity, specificity, and Kappa scores were calculated using a general method outlined 
by Fleiss(19). Pearson correlations were computed for the log-transformed task exposures 
assessed by the IH rating and IH data method and on the log-transformed participant 
LTWA exposures by the JEM, IH rating, and IH data methods. Spearman rank 
correlations were computed to assess rank agreement. Relative agreement for the task 
exposure estimates and participant LTWA exposures comparing the IH data method to 
the IH rating and JEM methods was assessed overall and by case status using a one-way 
random single measure of the intraclass correlation coefficient based on the convention of 
Shrout and Fleiss(20). Linear regression on log-transformed values was used to assess the 
relationships between task exposures assessed using the two methods and to compare 
participant LTWA exposures from the IH rating and JEM methods compared to the IH 
data method. Unconditional logistic regression was used to model CBD as a function of 
LTWA beryllium exposure. To facilitate comparison of separate models, only the LTWA 
exposures from the three different exposure assessment methods were included in the 
models. Based on the lack of an exposure-response relationship for BeS identified in 




Study population and demographic characteristics 
Study population and demographic characteristics are presented in detail in 
Chapter 3 including data tables. However, important details are presented briefly here. 
There were 386 former RFETS workers in the study population including 255 controls 
with potential beryllium exposure, 61 subjects with confirmed CBD, and 70 individuals 
classified as BeS due to two abnormal BeLPTs. Participants were predominately male 
(88.3%), Caucasion (97.7%), and non-smokers (94.0%). The median year of hire at the 
facility was 1969 and ranged from 1952 to 1998. The typical participant worked at the 
facility for approximately 15 years, although the minimum time at the facility was less 
than three months and the maximum more than 40 years. The only important difference 
in demographic characteristics that may relate to exposure was that BeS cases typically 
worked fewer years at the facility (median=12.6 years) as compared to controls 
(median=15.8 years, p=0.020). 
 
Task exposures 
Task exposures assigned using the IH data and IH rating method are shown in 
Table IV-I separated by task and exposure type. Overall, for the 50 task/exposure type 
combinations, exposures assigned using the IH rating method were higher than those 
assigned using the IH data method for 74% (37/50) including 70% (19/27) of the direct 
exposure combinations and 78% (18/23) of the indirect exposure combinations. However, 
of the 13 exposure combinations where the IH data estimate was higher than the IH rating 
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estimate, six had estimates much greater than the IH data estimates including: 1) 
beryllium casting and mold breakout with an IH data estimate of 73 µg/m3 compared to a 
rating estimate of 10 µg/m3; 2) filter replacement and testing with an IH data estimate of 
23.9 µg/m3 compared to an IH rating estimate of 4.0 µg/m3; and 3) crushing beryllium 
parts/shapes with an IH data estimate of 36.4 µg/m3 compared to an IH rating estimate of 
3.0 µg/m3. The mean absolute difference between the paired estimates was 4.1 µg/m3. 
However, this difference was skewed by a few large differences as mentioned above. The 
median absolute difference was 0.43 µg/m3 which indicates that for half the exposure 
scenarios the two estimates were within ±0.43 µg/m3.  
Table IV-II shows summary statistics of the task exposures by the two assessment 
methods. There were significant differences between the pairs of task exposure estimates 
(p < 0.001) by Wilcoxon Rank Sum tests with IH rating estimates generally higher than 
IH data estimates. The intraclass correlation coefficients between all task exposure 
estimates using the two methods was 0.17 suggesting poor agreement. However, given 
that 75% of the exposure time of the participants occurred in 10 tasks, the intraclass 
correlation coefficient for exposure assignments for those 10 tasks was 0.74 suggesting 
that for the majority of the exposures in terms of exposure time there was good 
agreement. In addition, a Pearson correlation coefficient of 0.82 (p < 0.001) for the log-
transformed task exposure estimates suggests increases and decreases in IH rating 
estimates were usually accompanied by increases and decreases in IH data estimates of 
fairly consistent magnitude. The Spearman rank correlation of 0.81 (p < 0.001) also 
suggested similar rank-order of the estimates. A linear regression between the log-
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transformed estimates (Figure 4-1) suggested that 67% of the variation in the IH data 




As shown in Table IV-III, while all participants had assigned LTWA exposures 
using the IH data and IH rating methods, only 86% (332/386) of the participants had 
assigned exposures using the JEM method which included 48 BeS cases, 38 CBD cases, 
and 187 controls. In addition, 273 (82%) of the 332 individuals with an assigned LTWA 
exposure using the JEM method were assigned an exposure of zero. Table IV-IV 
compares reported exposure characteristics from exposure interviews used in the IH 
rating and data methods among participants assigned zero and non-zero LTWA 
exposures using the JEM method. All (100%, 59/59) of the participants that were 
assigned non-zero exposures using the JEM method were also identified as having been 
exposed to beryllium through later exposure interviews. Furthermore, those assigned a 
non-zero exposure were more likely to have directly altered a beryllium part (80.0%, p < 
0.001) as compared to those assigned a zero exposure (22.7%). Only seven of the 
participants with non-zero JEM exposure did not have direct exposure to beryllium. 
Those assigned a non-zero JEM exposure also spent a greater percentage of their time 
working directly or indirectly with beryllium (43.1% vs. 27.6%, p < 0.001) and had a 
higher LTWA exposure as determined using the IH data method (median=0.17 vs. 
median=0.02, p < 0.0001). Of those assigned zero exposure using the JEM method, 
nearly 50% had assigned LTWA exposures from the IH data method of less than or equal 
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to 0.02 µg/m3 which would have been considered a very low exposure in the late-1990s 
when the JEM was constructed. When combined, this evidence suggests that the JEM 
was effective in assigning exposures to those individuals frequently working directly with 
beryllium and  was much less effective at identifying workers with only indirect exposure 
to beryllium. 
 
Comparing exposures by case status 
When comparing LTWA exposures assigned using the IH data and IH rating 
methods, there were no significant differences between the methods by case status 
including exposures assigned to controls (medians: 0.03 µg/m3 and 0.04 µg/m3, 
respectively), BeS cases (medians: 0.009 µg/m3 and 0.01 µg/m3, respectively), and CBD 
cases (medians: 0.07 µg/m3 and 0.10 µg/m3, respectively). Exposures assigned using the 
JEM method differed significantly from those assigned using either the IH data or IH 
rating methods for CBD cases, BeS cases, and controls (median=0 µg/m3 and p < 0.0001 
for all). However, when comparing exposures across case status within each individual 
exposure assessment method, the same conclusion was made regardless of method; 
namely exposures for CBD cases were significantly higher than exposures for either BeS 
cases or controls (CBD vs. controls: IH data method p=0.012, IH rating method p=0.024, 
JEM method p=0.024; CBD vs. BeS: IH data method p=0.002, IH rating method 
p=0.006, JEM method p=0.011). In addition, there were no differences in LTWA 
exposures between BeS cases and controls for any of the exposure assessment methods. 
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Paired exposure comparisons by assessment method 
Table IV-V shows the relative and absolute differences in pairs of LTWA 
exposure assignments by case status and exposure assessment method. Paired LTWA 
exposure assignments were significantly different (p< 0.0001) when comparing either the 
IH data method to the IH rating or to the JEM methods. This difference was consistent 
across cases and controls. Typically, these differences were relatively small with median 
relative differences of less than 0.001 µg/m3 when comparing the IH data and IH rating 
methods and 0.01 µg/m3 when comparing the IH data and JEM methods. Figure 4-2 
shows the distribution of the relative differences in LTWA exposures between the 
methods. Compared to the IH data method (Figure 4-2a), the IH rating method tended to 
overestimate LTWA exposures for BeS cases and controls and underestimate LTWA 
exposures for CBD cases. Compared to the IH data method (Figure 4-2b), the JEM 
method tended to underestimate LTWA exposures for all participants. In both cases, there 
appeared to be more variability in the differences between LTWA exposures assigned to 
CBD cases than controls or BeS cases. The relative differences in LTWA exposure 
assignments between the IH data and IH rating methods were significantly greater for 
CBD cases as compared to controls (p=0.006). 
Absolute differences in the pairs of assigned LTWA exposures by method are also 
shown in Table IV-V. Overall, LTWA exposures assigned using the IH rating method 
were within ± 0.02 µg/m3 of those assigned using the IH data method for 50% of 
participants and within ± 0.15 µg/m3 for 75% of the participants. However, the absolute 
differences between the LTWA exposures assigned using the IH data and IH rating 
methods were typically greater for CBD cases compared to either BeS cases (p=0.007) or 
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controls (p=0.006). LTWA exposures assigned using the JEM method were within ± 0.03 
µg/m3 of those assigned using the IH data method for 50% of participants and within ± 
0.21 µg/m3 for 75% of the participants. The magnitude of these absolute differences did 
not change by case status. 
 
Sensitivity, specificity, and agreement 
Table IV-VI compares the sensitivity, specificity, and relative agreement of the 
JEM and IH rating methods to the IH data method. In this case, the IH data method was 
chosen as the “gold standard” due to its use of all available information on exposure at 
the facility. In order to perform these comparisons, “exposed” was defined as a LTWA 
exposure greater than 0.02 µg/m3, and “unexposed” was defined as a LTWA exposure 
less than or equal to 0.02 µg/m3. The specificity of the JEM method ranged from 0.93 to 
0.96 and did not differ significantly depending on case status. The cost of the relatively 
high specificity of the JEM was its relatively low sensitivity ranging from 0.19 to 0.40 
which appeared to be higher for CBD cases (0.40, 95% CI: 0.30-0.43) as compared to 
BeS cases (0.19, 95%CI: 0.09-0.23) and controls (0.25, 95% CI: 0.20-0.28). The 
specificity of the IH rating method ranged from 0.87 to 0.93 with no significant 
differences by case status. The sensitivity of the IH rating method ranged from 0.81 to 
0.90 and also did not differ by case status. In order to measure the relative agreement 
between the IH data method and the JEM and IH rating methods, a Kappa coefficient was 
calculated. This Kappa coefficient was compared to previous interpretations classifying 
the degree of agreement between two raters as outlined by Altman(21). For the JEM 
method compared to the IH data method, the Kappa coefficient ranged from 0.16 to 0.27 
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suggesting “poor” to “fair” agreement between the methods in terms classifying 
participants as exposed or unexposed.  For the IH rating method compared to the IH data 
method, the Kappa coefficient ranged from 0.71 to 0.77 suggesting “good” agreement 
between the methods. 
 
Correlation among the three exposure assessment methods 
Table IV-VII shows the Pearson and Spearman rank correlations between the 
assigned LTWA exposures for participants by case status. Pearson correlations were 
determined using the log-transformed LTWA exposures. Comparing IH data and IH 
rating methods, significant positive Pearson correlations were identified ranging from 
0.62 for controls to 0.68 for CBD cases. Rank order Spearman correlations were higher 
ranging from 0.91 to 0.96 suggesting very high agreement in the rank ordered LTWA 
exposures. Correlations between LTWA exposures assigned using the IH data and JEM 
methods were lower ranging from -0.04 for BeS cases to 0.47 for CBD cases. Rank order 
Spearman correlations were also lower ranging from 0.26 for BeS cases to 0.51 for CBD 
cases. Intraclass correlation coefficients comparing the relative agreement of the IH data 
and IH rating methods ranged from 0.48 to 0.61 suggesting “moderate” agreement 
between the methods. When comparing the IH data method to the JEM method using 
intraclass correlation coefficients, there was “fair” agreement for the CBD cases 
(ICC=0.26), but “poor” agreement for the BeS cases (ICC= - 0.13) and for the controls 
(ICC= - 0.01). Together, all these results suggested a much higher level of agreement 
between the IH data and IH rating methods which was confirmed via the linear regression 
analyses in Figures 4-3 and 4-4. Figure 4-3 shows the linear regression of the log-
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transformed IH data assigned LTWA exposures versus the log-transformed IH rating 
assigned LTWA exposures with a coefficient of determination (R2-value) of 0.42. While 
this analysis identified a significant linear relationship between the two methods, it also 
indicated that the IH rating method only explained approximately 42% of the variability 
in the log-transformed LTWA exposures assigned by the IH data method. A similar linear 
regression between the IH data method and the JEM method is presented in Figure 4-4. 
This regression suggested the relationship between the two methods, though statistically 
significant, was not very strong with a coefficient of determination of only 0.09. 
 
Differences in odds ratios by exposure assessment method 
Logistic regression models for the odds of CBD as a function of LTWA exposure 
are presented in Table IV-VIII for the three different exposure assessment methods. All 
three exposure assessment methods produced LTWA exposures that were significant 
predictors of CBD odds. The LTWA exposure assigned using the IH data method was the 
most highly significant in the logistic model (p < 0.001). Exposures assigned using the IH 
rating and JEM methods had similar significance levels (p=0.032 and p=0.034, 
respectively). Point estimates of the odds ratios for each unit increase in LTWA exposure 
ranged from 1.51 for the JEM method to 2.50 for the IH data method. However, the 95% 
confidence intervals from all three methods overlapped suggesting none of the three 
models produced a significantly different risk estimate. The output of the logistic 
regression models in terms of predicted probability of CBD by LTWA exposure level is 
presented in Figure 4-5. Probability profiles were very similar when using the IH data 
and IH rating methods with very little difference in the predicted probability of CBD with 
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increasing LTWA exposure. On the other hand, the curve showing the predicted 
probability of CBD produced using the JEM LTWA exposures was somewhat flatter with 
smaller increases in probability with increasing exposure. Odds ratio point estimates for a 
LTWA exposure of 2.0 µg/m3 (Table IV-IX) would likely be interpreted differently with 
a nearly 6-fold increased odds of CBD using the IH data and IH rating methods and only 
a 2-fold increased odds of CBD using the JEM method. 
 
Discussion 
This report compared three methods of exposure assessment in an occupational 
case-control study providing evidence suggesting IHs can effectively assign exposures to 
industrial tasks based on task descriptions with good rank agreement compared to those 
produced by analyzing historical IH exposure measurements. Furthermore, these IH 
assigned task-based exposures can be incorporated into participant-reported task histories 
to create LTWA exposures of sufficient quality to produce very little attenuation in odds 
ratios for the exposure-disease relationship as compared to those produced using IH 
measurements. Though there was limited correlation between continuous participant 
LTWA exposure estimates produced by a JEM method compared to methods using self-
reported tasks, exposure-disease relationships produced by this JEM method were not 
substantially different from those produced using either the IH assigned exposures or 
those produced using actual IH data. 
Most published validation and reliability studies focusing on expert assignment of 
occupational exposures have focused on the ability of experts to assign a binary 
exposed/not-exposed rating or a categorical rating based on descriptive information 
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provided regarding the participant’s job title or industry. In these studies, investigators 
have found significant associations between expert rankings and IH measurements in 
nearly all studies with the proportion of variance explained ranging from 0.2 to 0.65 with 
a median of approximately 0.3.(22-25) However, we could identify only a single study that 
involved evaluation of expert exposures assigned on a continuous airborne concentration 
scale. Cherrie and Schneider (25) evaluated two IHs’ estimates of exposure using a 
subjective method based on descriptive information about the work environment 
compared to IH measurements for five different agents and identified Pearson correlation 
coefficients ranging from 0 to 0.93 with a median of 0.39. The overall correlation 
between our task exposure estimates from the IH data and IH rating methods was 0.81 
which is well within the range identified by Cherrie and Schneider. However, it should be 
noted that our comparison was between a less formal approach for assigning continuous 
exposure metrics versus Cherrie and Schneider’s structured approach. In addition, we 
compared our expert assignments to concentrations obtained from analysis of historical 
data rather than contemporary measurements. Cherrie and Schneider also found that their 
expert assessments were positively biased with ratios of the expert assessment to the 
measured levels ranging from 1.3 to 2.2. For our tasks, the expert assignments were 
positively biased most of the time, but the ratios of the IH assigned task exposure 
assignments to those based on IH data ranged from 0.04 to 16.7 with a median of 1.8. 
Overall, our IH rating method demonstrated that, at least in the beryllium 
industry, experienced IHs can assign exposures to tasks based solely on their professional 
judgment with good rank order agreement (rho=0.81) compared to those assigned using 
analyses of historical data. However, when considered on equivalent µg/m3 scales, task 
 150
exposures assigned using the IH rating method agreed poorly with those assigned using 
IH data (ICC=0.17). Much of this disagreement was likely due to our IH raters’ lack of 
familiarity with some rarer tasks such as filter replacement and testing on a beryllium 
contaminated ventilation system or crushing of beryllium parts or shapes. When 
considering only the common tasks occurring at the facility, those that comprise over 
75% of our participants’ exposed work time, there was good agreement on an absolute 
scale as evidenced by an intraclass correlation coefficient of 0.74. 
JEM methods were conceived as an efficient method to assess exposures for case-
control studies involving thousands of workers or community members based on job title. 
As such, the major limitation of JEM methods is the potential misclassification of 
exposure introduced due to variability of exposure related tasks within a job title.(26) A 
review on the reliability and validity of common exposure assessment methods for case-
control studies indicated that compared to expert assessment or self-reports of exposure, 
JEMs typically have low sensitivity, most often below 0.5, but fairly good specificity, 
generally above 0.85.(27) In our evaluation, the JEM method was clearly less sensitive 
than the IH data method with sensitivities ranging from 0.19 to 0.40. Also concerning, 
was the differential sensitivity of the JEM method compared to the IH data method. The 
sensitivity of the JEM was higher for CBD cases (0.40) as compared to either BeS cases 
(0.19) or controls (0.25). Thus, the use of the JEM method as the primary exposure 
assessment method may result in differential misclassification of exposures and potential 
bias away from the null for the case control study. However, in defense of the JEM 
method, it was much more efficient than the other two methods. The JEM method 
required conducting only a few hundred interviews to assign exposures to multiple 
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chemicals to the entire known workforce of more than 13,000 workers. In addition, the 
method was highly specific with specificities ranging from 0.93 to 0.96 suggesting a high 
level of confidence that those identified as exposed were truly exposed. Finally, the JEM 
method, even with its limitations, produced CBD odds estimates that were not 
substantially different from those produced using the other more time-intensive methods. 
Based on the comparability of the task exposure estimates using the IH rating and 
IH data methods for the tasks comprising the majority of the participants’ exposed work 
time, it was not surprising that incorporation of these task exposures into identical data 
matrices of worker job and task times produced similar measures of LTWA beryllium 
exposure. Typically, exposures for the same worker produced by the IH data and IH 
rating methods were within ± 0.02 µg/m3. However, possibly concerning, was that there 
were larger absolute differences in the two LTWA exposure assignments for CBD cases 
as compared to BeS cases or controls. This may suggest either differential 
misclassification for one of the two methods, or the more likely explanation that since 
CBD cases incurred greater total beryllium exposure, differences in task exposure 
estimates were magnified for CBD cases as compared to others. Overall measures of 
sensitivity (0.91), specificity (0.85), and agreement (kappa=0.76) suggested a high degree 
of comparability between the IH data and rating methods in identifying those truly 
exposed and those truly not exposed. There was excellent rank correlation between the 
two methods (rho=0.93) which was likely most responsible for the very similar logistic 
regression coefficients in evaluating CBD odds. Intraclass correlation coefficients (0.48 
to 0.61) also suggest moderate to good agreement on an absolute scale. Overall, LTWA 
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exposure estimates produced using the IH rating method explained approximately 42% of 
the variability in the LTWA exposure estimates produced using the IH data method. 
The most important aspect of any exposure assessment activity for epidemiology 
studies is to identify how exposure affects disease status. In general, non-differential 
misclassification of exposure biases the exposure-response relationship towards the null. 
In a logistic regression analysis, this bias towards the null is manifested as an attenuated 
odds ratio for the exposure covariate. Interestingly, in our analyses, use of either the 
LTWA exposure estimate produced using the IH rating method or using the IH data 
method resulted in very similar odds ratios for the continuous exposure covariate (2.50, 
95% CI: 1.47-4.26 for the IH data method and 2.36, 95% CI: 1.08-5.19 for the IH rating 
method). Thus, compared to the IH data method, the more efficient IH rating method 
attenuates the point estimate of the odds ratio by only about 5%. This is interesting 
considering that the IH rating method relied on a single index or estimate of task 
exposure for all exposure time periods as compared to the IH data method which had up 
to three time-based exposure estimates for each task. Use of LTWA exposure 
assignments produced by the JEM method in a logistic regression model produced a 
lower odds ratio estimate (1.51, 95% CI: 1.03-2.22). Attenuation of the JEM odds ratio 
compared to the IH data odds ratio was approximately 40%. This larger attenuation was 
not surprising due to the low sensitivity of the JEM method. Interpretations of CBD risk 
covering the relevant range of possible beryllium exposures (0.05 to 2.0 µg/m3) were 
very similar using either the IH rating or IH data methods. However, at the higher 
average exposure levels, the attenuation of the odds ratio from the JEM method would 
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likely result in the acceptance of a higher occupational exposure level due to lower 
identified CBD odds. 
 
Limitations 
All three exposure assessment methods likely had significant exposure 
misclassification that could have impacted our results. Cumulative exposures and 
resulting LTWA exposures may have been overestimated for BeS/CBD cases using all 
three methods as exposures accrued until the date of BeS or CBD diagnosis which was 
likely much later than the date of disease development. The JEM method relied on 
interviews with only a few individuals from each job title to determine work tasks. This 
likely resulted in both under and over estimation of beryllium exposures for other 
individuals within the same job title due to variation in work tasks within a job title. The 
use of IH judgment to assign exposures to tasks clearly resulted in overestimation of 
exposures for some individuals and underestimation of exposure for others. The use of IH 
data from other facilities may have impacted the task exposure estimates in the IH data 
method. However, in assigning exposure estimates to tasks rather than individuals for all 
of these methods, exposure misclassification should have been non-differential. Based on 
the available IH exposure data from the RFETS facility, it is unlikely that we could have 





This study was designed to evaluate three different methods of retrospective 
occupational exposure assessment for a case-control study of BeS and CBD in a nuclear 
weapons facility. We identified that a method of task exposure assessment relying solely 
on the professional judgment of industrial hygienists performed similarly to a method 
involving extensive analyses of historical industrial hygiene exposure measurements in 
terms of rank order assessment of average task exposure. Continuous estimates of task 
exposure in µg/m3 provided by “expert” IH assessors were able to explain 65% of the 
variability in the task exposures assigned based on historical IH exposure measurements. 
In addition, we confirmed the widely reported high specificity and low sensitivity of a 
facility-specific job exposure matrix method. Use of any of the three exposure assessment 
methods resulted in estimates of increasing odds of CBD with increasing LTWA 
exposure levels that were not statistically different. Odds ratio point estimates for the 
odds of CBD for each unit increase in LTWA beryllium exposure were attenuated by 
approximately 5% using the “expert” assessment method and approximately 40% using 
the JEM method, both compared to the method using historical IH data. However, 
regardless of the exposure assessment method, this study demonstrates an exposure-
response relationship between LTWA exposure and CBD and the need to reduce the 
current OSHA permissible exposure limit of 2.0 µg/m3. 
  
Table IV-I – Task exposure estimates from IH data method and IH rating method 


























Assembly/Inspection        
 General assembly work with Be parts ‘52-‘05 0.13e     1.0 
 Hand polishing or etching Be parts ’52-‘85 1.0e ‘86-‘05 0.14   3.0 
 Brazing/Welding Be parts  ’52-‘85 1.32e ‘86-‘05 0.7   1.5 
 Inspection or handling of Be parts ’52-‘85 0.71e ‘86-‘05 0.15   0.2 
 Work within 5 feet of Be inspection operationsd ’52-‘85 0.36e ‘86-‘05 0.075   0.5 
 Work in same room as Be inspection operationsd ’52-‘85 0.07e ‘86-‘05 0.015   0.05 
 Work in same building as Be inspection operationsd ’52-‘85 0.007e ‘86-‘05 0.0015   0.02 
Machining        
 Cutting Be with a band saw ‘52-‘05 1.78e     2.0 
 Machining Be parts (mill, lathe, bore) ’52-‘74 2.56 ‘75-‘85 1.19e ‘86-‘05 0.052 1.0 
 Hand grinding of Be parts ‘52-‘05 0.56e     1.5 
 Machine grinding Be parts ’52-‘74 3.16 ‘75-‘05 0.56e   1.5 
 Machining BeCu parts ‘52-‘05 0.09     0.1 
 Work within 5 feet of a Be machining operationd  ’52-‘74 1.28 ‘75-‘85 0.6e ‘86-‘05 0.026 0.5 
 Work in same room as a Be machining operationd ’52-‘74 0.35 ‘75-‘85 0.16e ‘86-‘05 0.007 0.2 
 Work in same building as a Be machining operationd  ’52-‘74 0.035 ‘75-‘85 0.016e ‘86-‘05 0.0007 0.02 
Foundry        
 Be casting and mold breakout (old foundry,444) ’52-‘85 73.0e ‘86-‘05 2.0   10.0 
 Be casting and mold breakout (new foundry, 865) ‘52-‘05 2.0e     5.0 
 Work within 5 feet of Be casting (old foundry, 444)d ’52-‘85 36.0e ‘86-‘05 1.0   1.5 
 Work within 5 feet of Be casting (new foundry, 865)d ‘52-‘05 1e     1.5 
 Work in same room as Be casting (old foundry, 444)d ’52-‘85 7.3e ‘86-‘05 0.1   1.0 
 Work in same room as Be casting (new foundry, 865)d ‘52-‘05 0.2e     1.0 
 
aSpecifies the time period of similar exposure for the task. Tasks did not necessarily occur in every year in the time period from IH data method 
bSpecifies the arithmetic mean of the exposure for the task and time period combination in µg/m3 from IH data method 
cTask exposure estimate from IH rating method. 
dFor these tasks, there was only indirect exposure to beryllium. 
eSpecifies time period estimate relevant to compare with IH rating method 155 
  
 
Table IV-I (continued)– Task exposure estimates from IH data method and IH rating method 


























Forming         
 Hot pressing of Be parts ’52-‘05 1.03e     2.0 
 Rolling Be parts (sheet rolling) ’52-‘05 0.18e     1.0 
 Cutting Be using a shear ’52-‘05 1.28e     1.0 
 Annealing/Heat treating Be parts ’52-‘05 0.2e     2.0 
 Work within 5 feet of Be rolling/pressingd ’52-‘05 0.3e     0.5 
 Work in same room as Be rolling/pressingd  ’52-‘05 0.06e     0.2 
 Work in same building as a Be rolling/pressingd ’52-‘05 0.006e     0.02 
Laboratory         
 Metallurgical testing of Be parts ’52-‘05 0.16e     2.0 
 Laboratory analysis of Be samples ’52-‘85 0.26e ’86-‘05 0.13   0.5 
 Work within 5 feet of Be laboratory operationd ’52-‘05 0.08e     0.1 
 Work in same room as a Be laboratory operationd ’52-‘05 0.016e     0.05 
 Work in same building as Be laboratory operationd ’52-‘05 0.002e     0.02 
Treating/Finishing         
 Plating/Chemical milling/Etching beryllium parts ’52-‘05 0.32e     1.5 
 Operating metal spray/plasma machine with Be ’52-‘05 0.52e     2.0 
 Grit blasting or sand blasting Be parts ’52-‘05 0.3e     1.5 
 Work within 5 feet of Be plating/chem. Millingd ’52-‘05 0.16e     0.5 
 Work in same room as a Be plating/chem. Millingd ’52-‘05 0.03e     0.5 
 Work in same building as a Be plating/chem. Millingd ’52-‘05 0.003e     0.02 
 
aSpecifies the time period of similar exposure for the task. Tasks did not necessarily occur in every year in the time period from IH data method 
bSpecifies the arithmetic mean of the exposure for the task and time period combination in µg/m3 from IH data method 
cTask exposure estimate from IH rating method. 
dFor these tasks, there was only indirect exposure to beryllium. 





Table IV-I (continued)– Task exposure estimates from IH data method and IH rating method 


























Maintenance and D&D         
 Cleaning Be contaminated machines/surfaces ’52-‘85 4.5e ‘86-‘94 2.25 ‘95-‘05 0.05 2.0 
 Maintenance on Be contaminated machines/equipment ’52-‘85 1.0e ‘86-‘94 0.18 ‘95-‘05 0.04 2.0 
 Filter replacement/testing on Be contaminated systems ‘52-‘05 23.9e     4.0 
 Work in same building as a Maint/D&D operationd ’52-‘85 0.045e ‘86-‘94 0.023 ‘95-‘05 0.0005 0.02 
Waste         
 Washing Be contaminated laundry ‘52-‘05 0.3e     1.5 
 Collecting Be waste materials (chip collecting) ’52-‘85 23.9e ’86-‘05 3.3   2.0 
 Crushing Be parts/shapes ’52-‘85 36.4e ’86-‘05 3.3   3.0 
 Be waste packaging/re-packaging ’52-‘85 0.6e ’86-‘05 0.31   1.0 
Miscellaneous         
 Oversight within 5 feet of unspecified Be activitiesd ’52-‘74 0.93 ‘75-‘85 0.42e ‘86-‘05 0.06 0.5 
 Oversight in same room as unspecified Be activitiesd ’52-‘74 0.18 ‘75-‘85 0.075e ’86-‘05 0.015 0.15 
 Oversight in same bldg as unspecified Be activitiesd ’52-‘74 0.026 ‘75-‘85 0.012e ‘86-‘05 0.001 0.02 
 
aSpecifies the time period of similar exposure for the task. Tasks did not necessarily occur in every year in the time period from IH data method 
bSpecifies the arithmetic mean of the exposure for the task and time period combination in µg/m3 from IH data method 
cTask exposure estimate from IH rating method. 
dFor these tasks, there was only indirect exposure to beryllium. 













Table IV-II – Summary of task exposures by IH data and IH rating methods (in µg/m3) 
 IH data method IH rating method 
Tasks Median Range IQR Median Range IQR 
P-valuea 
All tasks (n=50) 0.31 0.002-73.0 0.08-1.03 1.0 0.02-10.0 0.20-2.0 < 0.001 
Direct exposure tasks (n=27) 0.71 0.09-73.0 0.30-1.78 1.5 0.10-10.0 1.0-2.0 < 0.001 
Indirect exposure tasks (n=23) 0.075 0.002-36.0 0.016-0.36 0.20 0.02-1.5 0.02-0.50 < 0.001 





Figure 4-1 – Linear regression of the natural log of the IH data task exposure estimates 
vs. the natural log of the IH rating task exposure estimates showing data, regression line, 
and predicted IH data estimates in table below 





























 IH rating 
estimate (µg/m3) 
Predicted  
IH data estimate 
(µg/m3) 
 
 0.02 0.0084  
 0.05 0.024  
 0.10 0.053  
 0.20 0.11  
 1.0 0.73  
 1.5 1.1  
 2.0 1.6  
 5.0 4.5  






Table IV-III – Summary of subjects’ lifetime-weighted average beryllium exposures in µg/m3 by case status and exposure 
assessment method 
Subjects and exposure 
assessment methods n Mean sd Median Min 5
th %ile 25th %ile 75th %ile 95th %ile Max
All subjectsa           
 IH data method 386 0.25 0.79 0.03 0 0 0.001 0.17 1.00 10.7 
 IH rating method 386 0.18 0.32 0.03 0 0 0.002 0.21 0.86 2.00 
 JEM methodb 332 0.19 0.61 0 0 0 0 0 1.16 4.31 
Controlsa           
 IH data method 255 0.15 0.36 0.03 0 0 0.002 0.15 0.62 3.14 
 IH rating method 255 0.16 0.28 0.04 0 0 0.003 0.17 0.76 1.90 
 JEM methodb 225 0.16 0.57 0 0 0 0 0 0.92 3.87 
BeS casesa           
 IH data method 70 0.25 0.75 0.009 0 0 0.00003 0.08 1.43 4.58 
 IH rating method 70 0.19 0.38 0.01 0 0 0.00009 0.14 1.01 2.00 
 JEM methodb 54 0.09 0.33 0 0 0 0 0 0.88 2.00 
CBD casesa           
 IH data method 61 0.64 1.61 0.07 0 0 0.004 0.64 2.06 10.7 
 IH rating method 61 0.25 0.39 0.10 0 0 0.01 0.37 0.79 1.94 
 JEM methodb 53 0.38 0.87 0 0 0 0 0.07 2.24 4.31 
 aMedians (or underlying distributions) differ across exposure assessment methods by Kruskal-Wallis test (p < 0.001) 
bMedians (or underlying distributions) from JEM method differ significantly from other exposure assessment methods by 
  Mann-Whitney (p < 0.001) 
cCBD median exposures (or their underlying distributions) differ significantly from controls and BeS cases (p < 0.05) by 








Table IV-IV – Comparison of reported exposure characteristics from exposure interviews used in the 
IH rating and data methods among participants assigned zero and non-zero lifetime-weighted average 
exposures using the JEM method 








Any reported exposure to Be, n (%)a 237 (86.8%) 59 (100%)e < 0.001 
Highest reported Be exposure, n (%)a    
 Any direct Be exposure 161 (59.9%) 52 (88.1%) < 0.001 
 a. Directly alter Be part 62 (22.7%) 47 (80.0%) < 0.001 
 b. Contact with Be waste materials 70 (25.6%) 5 (8.5%) 0.003 
 c. Contact with finished Be part 29 (10.6%) 0 (0%) 0.004 
 Any indirect Be exposure 76 (27.8%) 7 (11.9%) 0.012 
 d. Work within 5 ft. of Be operation 23 (8.4%) 1 (1.7%) 0.094 
 e. Work in same room as Be operation 13 (4.8%) 1 (1.7%) 0.478 
 f. Work in same bldg as Be operation 40 (14.6%) 5 (8.5%) 0.293 
 No known exposure to Be 36 (13.1%) 0 (0%) < 0.001 
Mean percent of work time exposed to Be (median)b    
 Directly (categories a – c above) 8.9% (0.9%) 19.0% (9.2%) < 0.001 
 Indirectly (categories d – f above) 18.7% (4.4%) 27.7% (17.2%) 0.003 
 Directly or indirectly 27.6% (13.0%) 46.7% (43.1%) < 0.001 
Ever worked as a Be machinist, n (%)a 21 (7.7%) 27 (45.8%) < 0.001 
Lifetime-weighted exposure from IH data method    
 Mean (median)b 0.21 (0.02) 0.51 (0.17) < 0.001 
 ≤ 0.02 µg/m3a 136 (49.8%) 9 (15.2%) < 0.001 
 aCompared using χ2 or Fisher’s exact method 






Table IV-V- Relative and absolute differences between subjects’ lifetime-weighted average exposures by exposure assessment 
method 
Relative differencesa Absolute differencesb Comparison 
Mean Median IQRc Mean Median IQRc 
IH data method vs. IH rating method       
 Overall 0.07 -0.00006 -0.03-0.17 0.20 0.02 0.0009-0.15 
 Controls -0.009 -0.0005d -0.05-0.002 0.13 0.02e 0.001-0.12 
 BeS cases 0.06 0 -0.02-0.0006 0.20 0.009e 0.00004-0.17 
 CBD cases 0.39 0d -0.02-0.13 0.50 0.05e 0.005-0.37 
IH data method vs. JEM method       
 Overall 0.08 0.01 0-0.10 0.32 0.03 0.002-0.21 
 Controls 0.001 0.01 0.00002-0.09 0.24 0.04 0.003-0.20 
 BeS cases 0.19 0.007 0-0.05 0.34 0.02 0.0004-0.21 
 CBD cases 0.30 0.01 0-0.19 0.62 0.07 0.004-0.58 
 aDifferences in paired exposures (IH data average exposure minus other method) 
bAbsolute differences in paired exposure (absolute value of IH data average exposure minus other method) 
cInterquartile range 
dSignificant difference in median difference (p=0.006) by Mann-Whitney test. 
eSignificant difference in absolute difference by Mann-Whitney tests (p=0.006 vs. BeS and p=0.010 vs. controls) 




Figure 4-2 – Box and whiskers plots showing relative differences in subjects’ average 
exposures by exposure assessment method 
 
a. IH data method minus IH rating method 






b. IH data method minus JEM method 











Table IV – VI – Measures of sensitivity and specificity comparing exposure assessment methods using an average 
exposure cutoff of 0.02 µg/m3 as zero exposure 
Methods and subjects compared Sensitivitya Specificityb Kappac 
IH rating method vs. IH data method    
 All subjects (n=386) 0.91 (0.88-0.94) 0.85 (0.81-0.88) 0.76 (0.69-0.82) 
 CBD cases (n=61) 0.90 (0.81-0.96) 0.81 (0.63-0.92) 0.71 (0.44-0.87) 
 BeS cases (n=70) 0.87 (0.74-0.94) 0.90 (0.80-0.96) 0.77 (0.54-0.90) 
 Controls (n=255) 0.93 (0.88-0.96) 0.84 (0.79-0.88) 0.77 (0.67-0.84) 
JEM vs. IH data method    
 All subjects (n=332) 0.27 (0.23-0.29) 0.94 (0.89-0.97) 0.19 (0.11-0.24) 
 CBD cases (n=53) 0.40 (0.30-0.43) 0.94 (0.75-1.0) 0.27 (0.04-0.33) 
 BeS cases (n=54) 0.19 (0.09-0.23) 0.96 (0.87-1.0) 0.16 (-0.04-0.23) 
 Controls (n=225) 0.25 (0.20-0.28) 0.93 (0.87-0.97) 0.16 (0.06-0.22) 
 aSensitivity with 95% confidence interval 
bSpecificity with 95% confidence interval 
cKappa score with 95% confidence interval 










Table IV-VII – Correlations between subjects’ lifetime-weighted average exposures by exposure assessment method and 
case status 
Methods and subjects compared Pearson ra 
(log-scale) 
Spearman rho ICCb 
IH data method vs.IH rating method    
 All subjects (n=386) 0.65 0.93 0.54 
 CBD cases (n=61) 0.68 0.91 0.61 
 BeS cases (n=70) 0.75 0.96 0.48 
 Controls (n=255) 0.62 0.91 0.56 
IH data method vs. JEM method    
 All subjects (n=332) 0.31 0.34 0.06 
 CBD cases (n=53) 0.47 0.51 0.26 
 BeS cases (n=54) -0.04 0.26 -0.13 
 Controls (n=225) 0.25 0.29 -0.01 
 aBased on log-transformed exposure measures 




Figure 4-3 – Linear regression of the natural log of the IH data lifetime-weighed average 
exposure estimates vs. the natural log of the IH rating lifetime-weighted average 
exposure estimates showing data, regression line, and predicted IH data lifetime-weighted 
average exposure estimates in table below 




























 IH rating 
estimate (µg/m3) 
Predicted  
IH data estimate in µg/m3 
(95% CI) 
 
 0 0.02 (-0.006-0.05)  
 0.02 0.04 (0.01-0.07)  
 0.05 0.07 (0.04-0.09)  
 0.1 0.11 (0.09-0.13)  
 0.2 0.19 (0.17-0.21)  
 0.5 0.39 (0.36-0.43)  
 1.0 0.66 (0.59-0.72)  
 2.0 1.03 (0.93-1.14)  




Figure 4-4 – Linear regression of the natural log of the IH data lifetime-weighed average 
exposure estimates vs. the natural log of the JEM lifetime-weighted average exposure 
estimates showing data, regression line, and predicted IH data lifetime-weighted average 
exposure estimates in table below 






















 JEM estimate 
(µg/m3) 
Predicted  
IH data estimate in µg/m3 
(95% CI) 
 
 0 0.12 (-0.09-0.16)  
 0.02 0.13 (0.10-0.16)  
 0.05 0.14 (0.11-0.17)  
 0.1 0.16 (0.12-0.19)  
 0.2 0.18 (0.15-0.22)  
 0.5 0.26 (0.21-0.30)  
 1.0 0.35 (0.28-0.42)  
 2.0 0.48 (0.37-0.60)  






Table IV-VIII– Multivariate logistic regression models for odds of CBD considering lifetime-weighted average exposure by three 
different exposure assessment methods 
Exposure assessment method and independent variables Regression coefficient 
Standard 
error P value OR (95% CI) 
IH data method     
 Intercept -1.68 0.16 < 0.001  
 Per unit increase in average Be exposure (µg/m3) 0.92 0.27 < 0.001 2.50 (1.47-4.26) 
IH rating method     
 Intercept -1.60 0.17 < 0.001  
 Per unit increase in average Be exposure (µg/m3) 0.86 0.40 0.032 2.36 (1.08-5.19) 
JEM method     
 Intercept -1.55 0.16 < 0.001  












Figure 4-5 – Logistic regression output for odds of CBD (models shown in Table IV-VII) 
showing predicted probability of CBD by lifetime-weighted average beryllium exposure. 
Each line shows prediction of separate model 























Table IV-IX – Odds ratio estimates by lifetime-weighted average exposure from logistic 




IH data method 
model 




0.05 µg/m3 1.05 (1.02-1.07) 1.04 (1.00-1.09) 1.02 (1.00-1.04) 
0.10 µg/m3 1.10 (1.04-1.16) 1.09 (1.01 -1.18) 1.04 (1.00-1.08) 
0.20 µg/m3 1.20 (1.08-1.34) 1.19 (1.01-1.39) 1.09 (1.00-1.17) 
0.50 µg/m3 1.58 (1.22-2.06) 1.54 (1.04-2.28) 1.23 (1.02-1.49) 
1.0 µg/m3 2.50 (1.47-4.26) 2.36 (1.08-5.19) 1.51 (1.03-2.22) 
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The overall goal of this dissertation research was to identify the contribution of 
exposure and genetic effects in the development of beryllium sensitization (BeS) and 
chronic beryllium disease (CBD) to better understand disease pathogenesis and provide 
important information to policy makers considering a new beryllium exposure standard. 
The first case-control study (Chapter 2) evaluated carriage of any glutamic acid at 
position 69 (E69) of the HLA-DPB1 gene in combination with beryllium exposure 
assessed using a method that combined individual subject interviews with “expert” 
assessment of task exposures by industrial hygienists. This study was performed with 
participants from an active nuclear weapons manufacturing facility, Y-12 in Oak Ridge, 
TN. A second, larger, case-control study was performed (Chapter 3) involving former 
workers from a decommissioned nuclear weapons manufacturing facility, Rocky Flats 
Environmental Technology Site (RFETS) in Arvada, CO. This study evaluated carriage 
of any E69 allele in addition to specific E69 alleles in combination with beryllium 
exposure assessed using a more intensive method that combined individual subject 
interviews with analyses of facility-specific and industry-wide industrial hygiene 
exposure measurements. The third study (Chapter 4) evaluated three methods of 
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beryllium exposure assessment including the methods used in Chapters 2 and 3 in 
addition to a more traditional job exposure matrix (JEM) method. The goals of this study 
were to determine the comparability of odds ratio estimates produced in previous 
chapters and to establish the most efficacious exposure assessment method for future 
studies on larger populations. 
 
Summary and significance of each study 
Exposure and genetics increase risk of beryllium sensitization and chronic beryllium 
disease at the Y-12 National Security Complex 
This case-control study of beryllium-exposed workers in the nuclear weapons 
industry was the first to examine the individual contributions of quantitative beryllium 
exposure estimates and HLA DPB1 E69 status. The study confirmed increased 
susceptibility to BeS/CBD among carriers of the HLA DPB1 E69 with genotype 
frequencies similar to those reported in previous cross-sectional studies (1-8). In addition, 
similar HLA DPB1 E69 genotype frequencies were noted for cases of CBD and BeS 
supporting the notion that E69 status is likely important for antigen presentation and not a 
relevant marker for progression from BeS to CBD (9-11). We found evidence of an 
exposure-response for beryllium exposure and BeS/CBD in a combined group of BeS and 
CBD cases. We also confirmed that BeS cases occurred among workers with very low 
estimated exposures, as demonstrated by previous reports(12, 13). Most importantly, we 
demonstrated that high exposure and genetic susceptibility via HLA DPB1 E69 each 
individually conferred increased odds of BeS/CBD of similar magnitude and added new 
information suggesting that together these odds appear to be additive. The most important 
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practical implications were the confirmation that high exposure to beryllium conferred 
increased odds of BeS/CBD even in the absence of genetic susceptibility and that 
reductions in exposure should reduce the odds of BeS/CBD among carriers and non-
carriers of the E69 susceptibility marker. The study implied that establishment of new 
occupational exposure levels should be aimed at the most susceptible population, those 
with the E69 genetic variant, due to their higher risk of BeS/CBD at lower exposure 
levels. 
 
Exposure and genetics in beryllium sensitization and chronic beryllium disease: a case-
control study at Rocky Flats Environmental Technology Site 
This larger case-control study, involving twice as many cases of BeS and three 
times as many cases of CBD as compared to the study in Chapter 2, had additional 
statistical power to evaluate not only carriage of any E69 allele, but also carriage of 
specific E69 alleles. These genetic factors could be evaluated in combination with 
beryllium exposure assessed in a more comprehensive manner than in Chapter 2 due to 
the large number of industrial hygiene exposure measurements available from RFETS. In 
addition, this study was able to model the odds of BeS and CBD separately due to the 
larger numbers of cases. This was the largest case-control study of beryllium exposed 
workers to date. Unlike the study in Chapter 2, this study identified increased beryllium 
exposure for CBD cases compared with controls and BeS cases which was evident 
whether considering self-reported exposure assessments or quantitative exposure 
reconstructions. In contrast, there were no significant differences in exposure between 
BeS cases and controls. While increased odds of both BeS and CBD was conferred by 
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carriage of any E69 allele, these odds appeared to be differentially distributed based on 
E69 genotype with greater odds among carriers of the rarer non-*02 HLA-DPB1 E69 
alleles, and among HLA-DPB1 E69 homozygotes. We also found evidence supporting 
the additive relationship between exposure and genetic susceptibility via E69 in the odds 
of CBD as identified in Chapter 2 and provided evidence suggesting an exposure-
response relationship for CBD and lack thereof for BeS after adjusting for E69 genetic 
risk factors.  
The finding of an exposure-response relationship and the additive relationship 
between exposure and genetics in the risk of CBD has implications for standard setting in 
workplace, at a time when OSHA is reconsidering revising the currently out of date 
beryllium exposure standard. The models from this case-control study can be roughly 
extrapolated to project the probability of CBD for workers at Rocky Flats given the 
facility prevalence of CBD of 1.7% identified in a stratified sample of Rocky Flats 
workers by Kreiss et al.(13) and assuming the E69 genotypes of controls are representative 
of the entire workforce. Extrapolation of our models indicated the expected prevalence of 
CBD resulting from a 0.2 µg/m3 lifetime weighted average exposure was 1.5%. 
 
Comparison of three methods of retrospective exposure assessment in a case-control 
study of beryllium sensitization and chronic beryllium disease 
The third study compared three different, but related, retrospective exposure 
assessment methods applied to the participants of the case-control study in the second 
study. This study compared the exposure assessment methods used in Chapters 2 (IH 
rating method) and 3 (IH data method) and a more traditional job exposure matrix 
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method (JEM method). Results from this study suggested that a method of task exposure 
assessment relying primarily on the professional judgment of industrial hygienists (IH 
rating method) performed similarly to a method involving extensive analyses of historical 
industrial hygiene measurements (IH data method) in terms of rank order assessment of 
average task exposure. Participant exposure assignments using all three of the methods 
were significant predictors of increased CBD risk. Exposure misclassification likely 
attenuated the odds ratio point estimates for the risk of CBD by approximately 5% using 
the IH rating method and approximately 40% using the JEM method. These results imply 
that, in the case of beryllium exposures, using the combination of industrial hygienist 
assigned task-based exposures and participant-reported task histories can be an effective 
strategy to assign long-term exposure estimates to participants in an epidemiology study. 
These “expert” based long-term exposure estimates appear to only minimally attenuate 
the odds ratios for the exposure-disease relationship as compared to those produced using 
a large number of industrial hygiene measurements.  
 
Conclusions 
 These three studies confirm the importance of both beryllium exposure and E69 
genotype in the risk of CBD suggesting an additive relationship between the two. 
Furthermore, it appears that BeS and CBD risk is differentially distributed among E69 
genotypes with carrriers of rarer non-*02 E69 alleles at higher risk. These studies also 
provide additional evidence on the importance of extremely low beryllium exposures in 
the risk of BeS even after adjusting for genetic susceptibility. Finally, the studies provide 
evidence to validate a more efficient exposure assessment method based on task 
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exposures assessed using “expert” industrial hygiene assessment rather than resource-
intensive compilation and analysis of thousands of exposure measurements. 
 
Future Studies 
 Findings of this dissertation raised several questions for future investigation 
including: 
1. Investigation of other exposure metrics and their relationship to the development 
of BeS: These studies identified trends showing lower cumulative and lifetime-
weighted average beryllium exposures among BeS cases compared to controls. 
This information combined with the frequent anecdotal reports of BeS occurring 
at extremely low exposures suggest current exposure assessment strategies have 
not identified the appropriate exposure metric to predict BeS. As has been 
suggested by others (14), dermal exposure metrics should be further explored to 
evaluate the importance of alternate exposure pathways in the development of 
BeS. 
2. Investigation of alternate susceptibility genes in combination with exposure 
among cases without the E69 variant: Others (3, 6, 8) have identified a glutamic 
acid substitution at position 71 of the HLA-DRB1 gene as a potential alternate 
pathway for the development of BeS and CBD. Carriage of this gene has not been 
evaluated in combination with exposure. 
3. Investigation of the exposure effects on the severity of CBD: A diagnosis of CBD 
represents a wide spectrum of clinical effects ranging from the development of 
granulomas on biopsy without evidence of symptoms or impairment in lung 
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function to severe, disabling gas-exchange and other lung function abnormalities 
requiring medical treatment. Researchers have long hypothesized that CBD 
severity is related to the total lung burden of beryllium. However, to date, an 
effective scale for classifying CBD severity has not been developed. 
4. Investigation of alternate exposure-response relationships for CBD: Logistic 
regression models in analyses in this dissertation assumed a linear relationship 
between the log-odds of CBD and lifetime-weighted average exposure. Further 
analyses using methods allowing for non-linearity, such as fitting splines to the 




1. Richeldi, L., K. Kreiss, M.M. Mroz, B. Zhen, P. Tartoni, and C. Saltini: 
Interaction of genetic and exposure factors in the prevalence of berylliosis. 
American Journal of Industrial Medicine 32: 337-340 (1997). 
2. Richeldi, L., R. Sorrentino, and C. Saltini: HLA-DPB1 glutamate 69: a genetic 
marker of beryllium disease. Science 262: 242-244 (1993). 
3. Rossman, M.D., J. Stubbs, C.W. Lee, E. Argyris, E. Magira, and D. Monos: 
Human leukocyte antigen Class II amino acid epitopes: susceptibility and 
progression markers for beryllium hypersensitivity. American Journal of 
Respiratory and Critical Care Medicine 165: 788-794 (2002). 
4. Wang, Z., G.M. Farris, L.S. Newman, Y. Shou, L.A. Maier, H.N. Smith et al.: 
Beryllium sensitivity is linked to HLA-DP genotype. Toxicology 165: 27-38 (2001). 
5. Wang, Z., P.S. White, M. Petrovic, O.L. Tatum, L.S. Newman, L.A. Maier et 
al.: Differential susceptibilities to chronic beryllium disease contributed by 
different Glu69 HLA-DPB1 and -DPA1 alleles. Journal of Immunology 163: 1647-
1653 (1999). 
6. Maier, L.A., D.S. McGrath, H. Sato, P. Lympany, K. Welsh, R. Du Bois et al.: 
Influence of MHC CLASS II in susceptibility to beryllium sensitization and chronic 
beryllium disease. Journal of Immunology 171: 6910-6918 (2003). 
7. McCanlies, E.C., J.S. Ensey, C.R. Schuler, K. Kreiss, and A. Weston: The 
association between HLA-DPB1Glu69 and chronic beryllium disease and beryllium 
sensitization. American Journal of Industrial Medicine 46: 95-103 (2004). 
8. Saltini, C., L. Richeldi, M. Losi, M. Amicosante, C. Voorter, E. van den Berg-
Loonen et al.: Major histocompatibility locus genetic markers of beryllium 
sensitization and disease. European Respiratory Journal 18: 677-684 (2001). 
9. Snyder, J.A., E. Demchuk, E.C. McCanlies, C.R. Schuler, K. Kreiss, M.E. 
Andrew et al.: Impact of negatively charged patches on the surface of MHC class 
II antigen-presenting proteins on risk of chronic beryllium disease. J R Soc 
Interface 5: 749-758 (2008). 
 181
10. Snyder, J.A., A. Weston, S.S. Tinkle, and E. Demchuk: Electrostatic potential on 
human leukocyte antigen: implications for putative mechanism of chronic 
beryllium disease. Environmental Health Perspectives 111: 1827-1834 (2003). 
11. Fontenot, A.P., M. Torres, W.H. Marshall, L.S. Newman, and B.L. Kotzin: 
Beryllium presentation to CD4+ T cells underlies disease-susceptibility HLA-DP 
alleles in chronic beryllium disease. Proceedings of the National Academy of 
Sciences of the United States of America 97: 12717-12722 (2000). 
12. Kreiss, K., M.M. Mroz, L.S. Newman, J. Martyny, and B. Zhen: Machining risk 
of beryllium disease and sensitization with median exposures below 2 
micrograms/m3. American Journal of Industrial Medicine 30: 16-25 (1996). 
13. Kreiss, K., M.M. Mroz, B. Zhen, J.W. Martyny, and L.S. Newman: 
Epidemiology of beryllium sensitization and disease in nuclear workers. American 
Review of Respiratory Disease 148: 985-991 (1993). 
14. Day, G.A., A.B. Stefaniak, A. Weston, and S.S. Tinkle: Beryllium exposure: 
dermal and immunological considerations. International Archives of Occupational 
and Environmental Health 79: 161-164 (2006). 
 
 
